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Abstract 
The DNA glycosylase NEIL3 is one of a family of proteins that release oxidized bases from 
DNA, thereby initiating base excision repair. NEIL3 gene expression is normally tightly 
regulated and expressed only in certain rapidly dividing cells, however, human NEIL3 
(hNEIL3) is also highly expressed in cells from metastatic tumours. In this project, full length 
hNEIL3 and truncations of the cDNA have been cloned into the pETDuet-2 expression vector 
for subsequent expression and purification. Each of the hNEIL3 truncations codes for the N-
terminal Fpg/Nei and H2tH domains essential for DNA glycosylase activity, but lack at least 
one of four C-terminal motifs unique to NEIL3. Using pETDuet-2, active truncated and full 
length hNEIL3 have been overexpressed in Escherichia coli and purified. Enzyme assays were 
performed using oligonucleotide substrates containing one of three oxidised bases, thymine 
glycol (TG), 5-hydroxyuracil (5-OHU) or 8-oxoguanine (8-oxoG). Results indicate that the 
recombinant hNEIL3 proteins are active on single-stranded DNA (ssDNA) substrates 
containing 5-OHU and TG but show only weak activity on 8-oxoG. In contrast, in double-
stranded DNA (dsDNA), activity on 5-OHU:G and TG:A was only weakly observed with 
nominal activity on 8-oxoG:C. The oxidised bases were then placed at three different sites in a 
model replication fork, at position -4 in ssDNA, at the fork junction (the last nucleotide in the 
dsDNA) and position +4 in dsDNA. For TG, hNEIL3 incised the fork substrate through β-
elimination at all positions and exhibited greater activity at the +4 position than in the equivalent 
dsDNA substrate. For 5-OHU, a similar level of β-elimination activity was observed at the -4 
and fork junction positions, but activity at the +4 dsDNA position was predominantly by β,δ-
elimination when the full length hNEIL3 protein was used. Again, only weak activity was 
observed on 8-oxoG fork substrates and a similar incision pattern was observed to that for 5-
OHU. Therefore, the results indicate that hNEIL3 acts as a bifunctional DNA glycosylase, 
either through β- or β,δ-elimination depending on the substrate lesion. For the first time it is 
shown that the C-terminal domains can influence the bifunctional DNA glycosylase activity of 
hNEIL3. These studies will help to define the biochemical function of this unique protein in 
both normal and malignant human cells. 
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1 INTRODUCTION 
1.1  DNA damage repair 
DNA damage can be caused by either endogenous sources generated during cell metabolism 
including hydrolysis, alkylation, oxidation or exogenous sources such as ultra violet radiation 
UV, ionizing radiation, and chemical agents. Failure to repair DNA damage could lead to loss 
of genomic integrity leading to apoptosis or cancer, however organisms have developed 
mechanisms of DNA repair to counter DNA damage (Hakem, 2008). 
DNA nucleotides are continually modified by hydrolysis and oxidation reactions. These types 
of reaction can result in many types of DNA damage. For example, spontaneous hydrolytic 
reactions can lead to depurination and deamination, the former resulting in an apurinic site in 
the DNA molecule and the latter resulting in the conversion of cytosine to uracil or adenine to 
hypoxanthine. Oxidation can lead to chemically altered bases and single- and double-strand 
strand breaks in the DNA molecule. 
UV radiation can cause covalent cross-linking of adjacent pyrimidines.  This can lead to the 
formation of a thymine dimer that interferes with DNA replication. Such alterations in 
nucleotide structure affect mainly one DNA strand at a given site. Ionizing radiation, however, 
can lead to double-strand breaks, which is more serious (Liu, et al., 2006). 
Oxidative DNA damage caused by reactive oxygen species (ROS) which are present in all 
aerobic cells causing oxidative DNA damage e.g. hydrogen peroxide, superoxide and hydroxyl 
radical (·OH) which produce a variety of oxidation products by attacking DNA at several 
positions. Oxidative damage causes single and double strand breaks. Examples of these 
products are 5-formyluracil, 2-oxoadenine and 8-oxoguanine and their level is dramatically 
induced by ionizing radiation of water (radiolysis) leading to hydroxyl radical formation 
(Naegeli, 1997). 
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DNA damage encountered by the cellular mechanisms of DNA repair to maintain genomic 
integrity. In response to the variety of DNA lesions, several DNA repair pathways have evolved 
in all organisms. The important DNA repair pathways for mammalian cells are direct repair, 
base excision repair (BER), mismatch repair (MMR), nucleotide excision repair (NER) and 
double-strand break repair (DSB), which includes non-homologous end-joining and 
homologous recombination. Also, the same mechanisms are used by cancer cells to survive 
treatment with genotoxic insults, e.g. ionizing radiation and chemotherapy (Naegeli, 1997).  
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1.2 Oxidative DNA damage 
Oxidation of nucleic acids can be a cofactor in the carcinogenic process (Poulsen et al., 2005). 
The most comprehensively examined product of ROS attack on the DNA molecule is the 
oxidation of guanine to 8-oxo-7,8-dihydroguanine (8-oxoG), particularly the mutagenic 
potential of this oxidised base lesion (Cadet et al., 2002). For example, methylene blue and 
UVA treatment of cells produces singlet oxygen molecules that generate 8-oxoG in DNA that 
is mutagenic because of its tendency to mispair with adenine during DNA replication. Thus, 
pre-mutagenic 8-oxoG is the most dominant product of guanine oxidation (Figure 1.1) causing 
G-to-T transversion mutations (Henderson et al., 2002; Hsu et al., 2004). 8-oxoG has been 
linked with cancer risk and its cellular effects have been studied extensively, indicating a role 
in carcinogenesis (Hegde et al., 2012). 8-oxoG can be further oxidised producing 
spiroiminodihydantoin (Sp) and guanidinohydantoin (Gh) in DNA (Niles et al., 2001; Jena and 
Mishra, 2012). 
The accumulation of 8-oxoG in DNA can be a major contributing factor in carcinogenesis and 
can be used as a cancer risk biomarker as the occurrence of this oxidative pre-mutagenic lesion 
in high concentrations in DNA leads to greater percentages of mutation accumulation over time, 
increasing the risk of cancer. These studies also linked life style with concentration levels of 
DNA oxidation products including 8-oxoG (McAuley-Hecht et al., 1994). 
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Figure 1.1 Guanine base oxidation leading to formation of 8-oxoG and FapyG  
Guanine oxidation producing FapyG and 8-oxoG which is further oxidized to form 
spiroiminodihydantoin (Sp) and guanidinohydantoin (Gh). (Adapted from Thiviyanathan et al., 
2008) 
 
Formamidopyrimidines (Fapy) are another mutagenic form of DNA oxidative damage caused 
by attack of ROS leading to the formation of FapyG (Figure 1.1) and FapyA (Jena and Mishra, 
2013). 
Cytosine can be attacked by hydroxyl radicals (•OH) and hydroperoxides or peroxyl radicals 
resulting in cytosine glycol (Figure 1.2.). Cytosine glycol can then either be deaminated to form 
uracil glycol, which is readily dehydrated to produce 5-hydroxyuracil (5-OHU), or dehydrated 
to form 5-hydroxycytosine (5-OHC) that can then be deaminated to form 5-OHU 
(Thiviyanathan et al., 2008). 
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Figure 1.2 Cytosine oxidation producing cytosine glycol followed by deamination-dehydration 
or dehydration-deamination forming uracil glycol, 5-OHC AND 5-OHU.  
(Adapted from Thiviyanathan et al., 2008) 
 
Thymine can also be oxidised to form a 5,6 radical adduct then a 5,6 OH-OOH intermediate by 
O2 addition, then the latter dehydrated to produce thymine glycol (TG). Oxidation and ionising 
radiation of thymine cause TG formation in DNA which has a stalling effect on DNA 
replication (Yoon et al., 2010). Thus unrepaired, accumulated oxidative damage may block 
replicative DNA polymerases causing replication fork stalling leading to double-strand breaks 
and cell apoptosis (Aller et al., 2007). 
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Figure 1.3 Thymine oxidation leading to formation of C5,6-OH radical adduct transforming to  
unstable intermediate by O2 addition then dehydrated to produce thymine glycol.  
(Adapted from Cadet and Wagner, 2013). 
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1.3 Base excision repair 
Base excision repair (BER) repairs most of the endogenous lesions such as oxidized bases and 
AP-sites as well as DNA single-strand breaks (Hegde et al., 2008). Studies have shown that the 
process is present in all organisms, form bacteria to eukaryotes including mammals. BER is an 
exceptional mechanism among the excision repair processes as individual base lesions are 
recognised and removed by specific DNA glycosylases. 
In addition to DNA base oxidation, ROS attacks the deoxyribose in DNA generating single- 
and double-strand breaks (sugar fragments of 3′ phosphates) and BER is also used to repair the 
resulting single-strand breaks. The 3′ blocking groups, including 3′-phosphate, 3′-
phosphoglycolaldethyde, and 3′-phosphoglycolate are also removed by enzymes in BER. The 
5′ terminus could consist either of phosphate or 5′-deoxyribosephosphate depending on the 
DNA glycosylase that has acted on the damaged base (Demple et al., 2002). 
DNA glycosylase initiate BER by recognizing and removing the damaged base by hydrolysing 
the N-glycosylic bond leaving either an abasic site (monofunctional DNA glycosylase), or a 
single-strand break (bifunctional DNA glycosylase). For the former, the apurinic/apyrimidinic 
(AP) site is then cleaved by AP-endonuclease-1 (APE1) giving a 5′-deoxyribophosphate (dRp) 
end that is removed by the dRPase activity DNA polymerase β (Polβ). The resultant single 
nucleotide gap is filled with the appropriate complementary nucleotide by Polβ  and the nick is 
sealed by the action of DNA ligase III/XRCC1 to complete the process (Prasad et al., 2002). 
If the damaged base is recognized by a bifunctional DNA glycosylase (DNA glycosylase/AP 
lyase), such as endonuclease III (NTH1) and 8-oxoguanine DNA glycosylase (OGG1), the AP-
site is cleaved by β-elimination creating a 3′ terminal sugar phosphate (3′-dRp) which is 
removed by APE1 leaving a gap with a 3′ OH end (Figure 1.4; Fortini and Dogliotti, 2007).  
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The DNA glycosylase, endonuclease VIII (Nei)-like proteins, NEIL1 and NEIL2 are also 
bifunctional, but they act by a different mechanism independent of APE1 as they remove the 
damaged base and cleave the AP-site by β/δ elimination generating a 3′ phosphate end which 
is then removed by polynucleotide kinase (PNK) (Wiederhold et al., 2004).  
1.3.1 Short patch BER 
BER is divided into two pathways, short- and long-patch BER.  While the first steps are the 
same, the gap-filling steps diverge. In short-patch BER, only one nucleotide is replaced and 
Polβ carries out both the steps required to produce a 5′ phosphate group and DNA synthesis 
(Figure 1.4). 
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Figure 1.4  Short patch BER 
Damaged bases in DNA are recognized by a DNA glycosylase (monofunctional or 
bifunctional). DNA glycosylases hydrolyse the N-glycosylic bond between the modified base 
and sugar backbone generating an AP-site that is then cleaved by APE1 to generate a 5ʹ-dRp 
that is removed by Polβ. This is followed by gap filling by Polβ and finally DNA ligase III 
seals the nick and completes the process (Adapted from Wallace 2012). 
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1.3.2 Long patch BER 
BER has been shown to undergo long patch repair in vivo, however, the choice of short- or long 
patch is still unclear (Figure 1.5; (Krokan, and Bjoras. 2013)). The first nucleotide is processed 
by Polβ as in short patch BER, then a replicative DNA polymerase (e.g. DNA polymerase 
δ or  ε) replaces the following 6 to 13 nucleotides. Replication factor (RF)-C is also involved 
in long patch BER to recruit the sliding clamp, proliferating cell nuclear antigen (PCNA) to the 
damage site of DNA. This provides a platform for DNA polymerase and flap endonuclease-1 
(FEN-1), which removes the displaced oligonucleotide fragment. Finally, the gap is sealed by 
DNA ligase I (Figure 1.5; Cappelli et al., 1997; Sleeth et al., 2004). 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5 Long patch BER 
A DNA glycosylase cleaves the glycosylic bond and the AP-site is incised by APE1 on the 5ʹ-
side. Thereafter, DNA polymerases δ or ε replace the strand with (RF)-C and PCNA in 
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displacement synthesis. The resulting oligonucleotide flap is removed by FEN-1 and the nick 
sealed by DNA ligase I. 
 
1.4 DNA glycosylases for oxidized bases 
The first DNA glycosylase discovered was uracil DNA glycosylase (UDG) in E. coli (Lindahl, 
1974). As cytosine deamination generates uracil and a G-U base pair is potentially mutagenic, 
the author looked for activities that could be used to identify uracil in DNA. Subsequently, other 
bacteria, yeast, plants, mammalian cells and mitochondria-specific UDGs were also 
characterized with similar enzyme activities (Hegde et al., 2008). In contrast to the relaxed 
specificity of the most DNA glycosylases for various substrates, UDG is specific for uracil in 
DNA as uracil fits tightly into the catalytic pocket of UDG. Mutational studies of UDG and 
crystal structures have revealed the structural basis of substrate specificity in preference to 
similar structures, such as C or T in the DNA. Because the uracil-binding pocket is narrow and 
deep and located in the positively charged groove of the enzyme, the DNA helix flips out to 
allow binding of DNA-uracil to the enzyme (Fromme and Verdine, 2003).  
 
Generally, a DNA glycosylase recognises only abnormal bases as substrates in DNA, including 
uracil. However, this is not always the case and at least three mammalian DNA glycosylases 
remove normal bases from DNA (TDG [thymine DNA glycosylase], MBD4 [methyl-CpG-
binding domain protein 4] and MUTYH) (Fromme and Verdine, 2002). The MutY gene was 
first described in E. coli; MutY deficiency induces spontaneous A-T, C-G transversion 
mutations (Fromme and Verdine, 2003). It mainly excises normal bases such as A & G from 
A-G and A (G): 8-oxoG base pair mismatches. Therefore, the gene MutY and its mammalian 
homolog MUTYH are basically essential, because they protect against oxidative base damage 
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- induced mutation by removing the base (A) in the nascent strand opposite 8-oxoG during 
DNA replication (Hegde et al., 2008). 
While uracil DNA glycosylase belongs to the UDG superfamily, a group of monofunctional 
DNA glycosylases, DNA glycosylases acting on oxidised base are divided into two families, 
either with a helix hairpin helix (HhH) domain or a helix 2-turn helix domain, and they are all 
bifunctional DNA glycosylases (Friedman and Stivers., 2010). Therefore, while the Nth 
(endonuclease III) superfamily has an HhH DNA binding domain, the Fpg/Nei 
(formamidopyrimidine-DNA glycosylase/endonuclease VIII) family members have a 
conserved H2TH motif. However, while their protein architecture may be different, some 
members of these families have common substrates (Hitomi et al., 2007). 
 
The Nth superfamily consists of E. coli endonuclease III (Nth), E. coli MutY, bacterial and 
yeast AlkA, yeast Ntg1 and Ntg2, mammalian NTH1, eukaryotic MUTYH and 8-oxoguanine 
glycosylase (OGG1). MutY, Nth and their eukaryotic homologs have an HhH structure tailed 
by a loop containing mainly glycine, proline and valine residues, and a conserved catalytic 
aspartate residue (McCullough et al., 1999; Prakash et al., 2012). Conversely, MutM (Fpg) and 
Nei have an H2TH motif and a zinc finger or a zincless finger motif for DNA binding (Hegde 
et al., 2008). The Fpg/Nei family consists of the bacterial proteins Fpg and Nei and their 
eukaryotic orthologs, Nei-like proteins NEIL1, NEIL2 and NEIL3.  
On the other hand, according to previous studies on E. coli, the oxidized base-specific DNA 
glycosylases were classified according to their tertiary structures into two group-families, AP 
lyase reaction activity and active site characteristics. The internal lyase residue is utilized by 
the Nth family as the active sits of the β elimination reaction, which in turn generates a 3′ 
phospho α,β-unsaturated aldehyde (3′ PUA) at the strand break. On the other hand, the other 
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members of E. coli Fpg family involving Nei (endonuclease VIII) catalyse β/δ elimination at 
the AP site by utilizing the N-terminal proline or valine as the nucleophile and remove the 
residual deoxyribose producing a 3′ phosphate terminus at the DNA strand break (Drohat and 
Maiti, 2014) 
1.5  Monofunctional DNA glycosylases in mammalian cells  
Uracil DNA glycosylases (UDG) superfamily proteins are all monofunctional DNA 
glycosylases that mainly recognize and remove uracil from DNA. Several UDGs has been 
expressed and purified: single-strand selective monofunctional uracil DNA glycosylase 1 
(SMUG1), nuclear uracil DNA glycosylase (UNG2) and mitochondrial uracil DNA glycosylase 
(UNG1). Additionally, the mismatch DNA glycosylases MBD4 and TDG are also members of 
this family (Wyatt, 2013). The catalytic domain of UDG is characterized by an α/β fold structure 
and UDGs show a varied substrate preference. Thus, while SMUG1 shows a preference for 5-
formyluracil and 5-hydroxymethyluracil, SMUG1 and UNG2 have been found to be active on 
5-OHU and 5,6-dihydroxyuracil, while SMUG1, UNG1 and UNG2 show activity on 5-
flurouracil (Krokan et al., 2013). 
Thymine DNA glycosylase is a mismatch DNA glycosylase. TDG is active on uracil and 
thymine mispaired with guanine and with preference to thymine. TDG is also active on several 
DNA lesions such as 5-carboxylcytosine, 5-formylcytosine with specificity for 5-halogenated 
pyrimidines e.g. 5-fluorouracil (Krokan et al., 2013; Morgan et al., 2007). MBD4 also acts on 
halogenated uracil e.g. 5-fluorouracil and 5-bromouracil. MBD4 which is an HhH family 
member, recognizes and removes thymine and uracil mispaired with guanine at CpG and 
deaminated CpG sites (Sjolund et al., 2012). 
MUTYH is a monofunctional DNA glycosylase, also a member of the HhH superfamily, acts 
on adenine mispaired with 8-oxoG. MUTYH is a homolog of the bacterial MutY protein and 
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they both remove adenine mispaired with FapyG (Greenberg, 2012). MUTYH has also been 
shown to have activity on DNA containing 2-hydroxyadenine paired with guanine or adenine. 
Also, mutated MUTYH is associated with colon cancer syndromes such as familial 
adenomatous polyposis (Markkanen et al., 2013; Palles et al., 2013; Wallace, 2014).  
The bacterial AlkA and Tag and mammalian alkyladenine DNA glycosylase (AAG) are 
functional homologs but have no structural similarity (Bjelland and Seeberg, 1996). AAG is a 
monofunctional DNA glycosylase that shows activity on a range of alkylated bases, including 
3-methyladenine, 3-methylguanine and 7-methylguanine, as well as deaminated adenine 
(hypoxanthine) and the lipid peroxidation product 1,N6-ethenoadenine (Lee et al., 2009). 
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1.6  Bifunctional DNA glycosylases 
The mammalian cell DNA glycosylases, OGG1, NTH1, NEIL1, NEIL2 and NEIL3 are 
responsible for the excision of a range of oxidised bases from DNA. In addition to this function, 
these bifunctional DNA glycosylases have an AP-lyase activity that results in strand incision, 
3́  to the AP-site that results from base excision. 
In the case of OGG1, the AP-lyase activity is often weak, therefore, the main product of OGG1-
catalysed cleavage is an undamaged AP site (Hegde et al., 2008). There are many differences 
found in the specific amino acid residues that recognise the damaged bases in DNA. Based on 
these differences, one is considered a unifying mechanism of DNA glycosylases activity and 
that is the extra helical flipping of the damaged deoxynucleotide into a lesion-specific 
recognition pocket. According to previous studies, all DNA glycosylases bind to the minor 
groove at the damage site causing a twist in the DNA molecule and the base lesion flips out of 
the DNA major groove (Slupphaug et al., 1996).  
As is evident from the discussion so far, DNA glycosylases can recognise a specific range of 
quite diverse substrate bases. Thus, the form of base damage is specific to each DNA 
glycosylase and only bases that can be accommodated in the binding pocket after base flipping 
will be recognised and excised. Therefore, the plasticity of the catalytic pocket plays a critical 
role, as it allows the fit of various substrate bases and allows a range of damaged bases to be 
excised by one DNA glycosylase (Hegde et al., 2008). 
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1.6.1 E. coli Fpg protein 
Formamidopyrimidine DNA glycosylase (Fpg/MutM), consists of 263 amino acids with 
molecular weight of 30.2 kDa. Fpg is a bifunctional DNA glycosylase with glycosylase and 
AP-lyase activity acting through β,δ-elimination. It possesses four DNA binding cysteine-zinc 
finger motifs and its active site has been located in its N-terminal domain. The first substrate 
that Fpg was reported to be active on was 2,6-diamino-4-hydroxy-N7-methyl-5-
formamidopyrimidine (Me-FapyGua; Chetsanga and Lindahl., 1979). The activity of Fpg has 
been extensively investigated using various methods and it has been shown to be active on 8-
oxoG, 5-hydroxycytosine (5-OHU), 5-OHU, FapyG and FapyA as well as the further oxidative 
product of 8-oxoG, Sp, in dsDNA. Studies have shown that 8-oxoG, FapyG and FapyA are the 
major physiological substrates of E. coli Fpg (Guo et al., 2010). 
 
1.6.2 E. coli Nei protein (Endonuclease VIII) 
 
 
 
 
 
Figure 1.6 Endonuclease VIII (Nei) protein structure 
Nei protein possesses one domain (H2TH) and consists of 263 amino acids. 
 
Endonuclease VIII (Nei) DNA glycosylase has been discovered in E. coli with molecular size 
of 29.7 consisting of 263 amino acids (Figure 1.6), The amino acid sequence and protein 
structure of Nei show homology to bacterial Fpg glycosylase (Melamede et al., 1994). Nei has 
been shown to have DNA glycosylase and AP-lyase activity on double-stranded DNA 
containing modified pyrimidines acting through β,δ-elimination. The substrate preference of 
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Nei has been investigated and the protein shows excision activity on 8-oxoG, TG, urea, β-
ureidoisobutyric acid, uracil glycol, 5-OHU, 5-OHC in DNA containing single modified bases 
(Boiteux et al., 1992).   
DNA with multiple lesions was also investigated and Nei has shown activity on pyrimidine 
derived DNA lesions such as 5-hydroxy-5-methyl-hydantoin (5-OH-5-MeHyd), 5-OH-6-
HUracil and 5-hydroxy-6-hydrocytosine as well as 8-oxoG:G and 8oxo-G:A in double-stranded 
DNA with lower activity on 8-oxoG:C. Nei also showed efficient activity on  multiple FapyA 
DNA lesions, but no activity on similar DNA containing FapyG (Hazra et al., 2000; Wiederholt 
et al., 2005). 
 
1.7 Mammalian bifunctional DNA glycosylases  
In mammalian cells there are five oxidized base specific DNA glycosylases. Previous studies 
determined that NTH1 and OGG1 are both members of the Nth family. NTH1 prefers oxidized 
pyrimidines as substrates, while OGG1 is primarily responsible for the removal of 8-oxoG and 
ring opened guanine, i.e. Fapy-G (Dalhus et al., 2009). More recently, two other human DNA 
glycosylases that are part of the Fpg/Nei family were discovered by searching human protein 
databases and they have been termed NEIL1 and NEIL2 respectively (Hazra et al., 2002). It 
has been mentioned that these enzymes are bifunctional glycosylases with broad substrate 
range. These were followed in the same year by the identification of a third paralog in human 
cells, subsequently termed NEIL3 (Morland et al., 2002; Liu et al., 2012). Amongst these three 
NEIL homologs, the N-terminal proline is present in NEIL1 and NEIL2, while NEIL3 possess 
a valine residue that acts as the active site nucleophile (Serre et al., 2002). Previous studies 
showed that both NEIL1 and NEIL2 enzymes prefer modified pyrimidine substrates and are 
closer to Nei than Fpg. 
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1.7.1 OGG1 protein 
OGG1 DNA glycosylase excises 8-oxoG from double-stranded DNA by cleaving the N-
glycosylic bond and incises the phosphodiester backbone on the 3́ side of the AP-site with its 
AP-lyase activity through β-elimination, resulting in a single-stranded break at the site of the 
oxidized base. Two human OGG1 proteins has been discovered (α-hOGG1, molecular weight 
of 38.8 kDa 345 amino acids and β-hOGG1, molecular weight of 47.2 kDa 424 amino acids). 
OGG1 is the major DNA glycosylase involved in removing 8-oxoG from eukaryotic cells 
(Wallace et al., 2012).  
Guanine is the base most susceptible to oxidative damage and 8-oxoG is quatitatively one of 
the principal oxidised bases found in DNA. 8-oxoG is a pre-mutagenic lesion as it can base pair 
with adenine as well as the canonical cytosine.  However, OGG1 knockout mice showed no, or 
only a slight increase in cancer frequency despite the increase of damage accumulation and 
mutation (Arai et al., 2006). However, a SNP variant of OGG1 (OGG1-S326C) has been 
detected in 23% to 41% of the Japanese and Caucasian population (Hung et al., 2005) and  this 
SNP has been associated with various diseases and syndromes including types of cancer such 
as kidney, head and neck, bladder, colorectal and lung cancers (Zhou et al., 2015). 
1.7.2 NTH1 protein 
Homologous to bacterial Nth, the mammalian NTH1 DNA glycosylase is an HhH superfamily 
member, consists of 312 amino acids and has a molecular weight of 34.4 kDa. NTH1 is a 
bifunctional DNA glycosylase with glycosylase-AP-lyse activity acting through β-elimination. 
NTH1 has overlapping substrate specificity with NEIL1 and recognizes and removes 5-OHU, 
5-OHC, urea and TG in DNA containing single and multiple DNA lesions. It has also been 
shown that FapyA is a major preferred substrate of NTH1 where NTH1 null mice showed 
accumulations of FapyA DNA damage (Hu et al., 2005; Chan et al., 2009). A SNP variant of 
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NTH1 (hNTH1-Asp239Tyr) has been found in 6.2% of the global population. The mutant 
variant has been purified and shows no DNA glycosylase activity which suggests that humans 
carrying this variant may be more susceptible to carcinogenesis. Also, it has been shown that 
overexpression of NTH1 is detected in around half of the cases of colorectal cancers in disease-
free survival, suggesting that NTH1 plays a major role in maintaining genome integrity in these 
patients (Koketsu et al., 2004). 
 
1.7.3 NEIL1 
 
 
 
 
Figure 1.7 Human NEIL1 protein possesses FpgNei superfamily, H2TH and Nei-DNA binding 
domains and consists of 390 amino acids. 
 
NEIL1 is a human homolog of the Nei bacterial protein (Nei-like), that has been identified in 
human cells (Hazra, et al., 2002; Morland et al., 2002). NEIL1 is one of the Fpg/Nei family of 
DNA glycosylases with more similarity of amino acid sequence to Nei than Fpg, The molecular 
size of NEIL1 is 43.7 kDa and 390 amino acids (Figure 1.7). The expression of NEIL1 is cell-
cycle dependent and it is principally expressed during S phase and therefore it is suggested to 
have a role in the repair of DNA damage during DNA replication. NEIL1 DNA glycosylase 
acts through a β/δ-elimination mode of action utilizing proline 2 at the N-terminus (Bandaru, et 
al., 2002; Hazra et al., 2002). As evidence of its importance in safeguarding genetic integrity, 
NEIL1 is found in the nucleus and mitochondria (Hu et al., 2005). The highest expression levels 
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of NEIL1 is detected in the thymus, pancreas and liver with lower expression in brain tissue 
(Morland et al., 2002; Izumi et al., 2003). The structure of NEIL1 has been studied by X-ray 
crystallography where it showed a lack of the conserved zinc-finger motif that is replaced by a 
zinc-less finger motif (Doublie et al., 2003). NEIL1 has proved to be active on Me-FapyG and 
oxidised pyrimidines in an oligonucleotide substrate with a single oxidative lesion. However, 
while no activity was observed on 8-oxoG:C the further oxidation products of 8-oxoG, Sp and 
Gh were substrates. NEIL1 was tested on multiple DNA lesions and proved to be active on 
FapyG and FapyA while it showed less activity on TG and 5-OH-5-MeHyd (Jaruga et al., 2004; 
Hazra et al., 2002).  
 
NEIL1 knockout mice and NEIL1 knockdown cells show accumulation of FapyG and FapyA 
but no 8-oxoG confirming the above in vitro studies and demonstrating NEIL1 preference to 
FapyG and FapyA. A study showed that FapyG is an overlapping substrate for NEIL1 and 
OGG1 when NEIL1 and OGG1 knockout mice show accumulation of FapyG, but 8-oxoG is 
accumulated only in OGG1 knockout mice confirming that NEIL1 does not recognise 8-oxoG 
containing DNA lesion in vivo (Liu et al., 2013). Also, it has been shown that NEIL1 knockout 
mice developed hepatocellular and pulmonary cancer in late stage of their life (Chan et al., 
2009). NEIL1 shows activity on lesions in quadruplex DNA structures and telomeric DNA 
context with preference for specific lesions such as Gh and no activity on TG or 8-oxoG 
confirming previous results (Zhou et al., 2013 and 2015). Interestingly, NEIL1 also proved to 
be active on DNA crosslinks induced by psoralen (Couve-Privat et al., 2007; Couve et al., 2009; 
Martin et al., 2017).  
Numerous polymorphic alternates has been detected and purified such as NEIL1-Asp252Asn, 
NEIL1-Cys136Arg, NEIL1-Ser82Cys, NEIL1-Pro208Ser, NEIL1-DGlu28 and NEIL1-
Gly83Asp, according to the National Institute of Environmental and Health Sciences Environ-
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mental Genome Project (Roy et al., 2007). NEIL1 SNP variants have been identified in a group 
of people representing the US population, where it has been found that SNPs occurred in 1% 
of that group.  Some of these variants have been found in cancer patients such as NEIL1-
Pro208Ser, which was found in patients of colorectal carcinoma and NEIL1-Gly83Asp, found 
in patients with cholangiocarcinoma, suggesting that people carrying those NEIL1 variants 
could be at higher risk of developing cancer (Cadet et al., 2010; Sampath et al., 2012). 
Furthermore, several types of NEIL1 SNPs have been identified as cancer associated variants 
(Dallosso et al., 2008; Forsbring et al., 2009). Although NEIL1 is one of the DNA glycosylases, 
it is believed that NEIL1 is involved in other DNA repair mechanisms such as nucleotide 
excision repair (NER). The evidence for this has been presented by a research group judging 
the accumulation of 8,5ʹ-cyclopurine-2ʹ-deoxynucleoside lesions in NEIL1 knockout mice 
where these lesions are repaired by NER not BER and suggested that NEIL1 may play a role in 
NER (Jaruga et al., 2010). The role of NEIL1 in NER is suggested as a result of NEIL1 protein 
interaction with the NER protein complex (Hegde et al., 2015).  
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1.7.4 NEIL2 
 
Figure 1.8  Human NEIL2 protein possesses FpgNei superfamily and H2TH super family 
domains and consists of 332 amino acids. 
 
NEIL2 is the smallest member of the Nei-like DNA glycosylase family and the human protein 
consists of 332 amino acids and is a 36.8 kDa protein (Figure 1.8). NEIL2 has DNA 
glycosylase/AP-lyase activity acting through β,δ-elimination (Hazra, et al., 2002; Dou et al., 
2003). Although NEIL2 does not share sequences homology with NEIL1, it possesses the same 
N-terminal proline 2 at the catalytic active site as NEIL1. It possesses the conserved H2TH and 
the zinc finger domains of E. coli Fpg/Nei and NEIL3. NEIL2 has been detected in both the 
nucleus and mitochondria. However, NEIL2 does not show a cell-cycle dependent expression 
pattern and therefore it has been suggested that NEIL2 acts in transcription-coupled DNA 
repair, further evidenced by the substrate preference of NEIL2 for single-stranded and bubble 
DNA structures which are created during transcription (Banerjee et al., 2011). 
NEIL2 shows efficient excision activity on 5OHU:G in double-stranded oligonucleotide 
substrates (Hailer et al., 2005). It showed lower activity when incubated with 5,6-diHU and 5-
OH-C and a very weak activity when incubated with TG or 8-oxoG containing substrates. 
However, NEIL2 also showed activity on the further oxidative products of 8-oxoG (Sp and Gh) 
in double-stranded DNA oligonucleotide substrates (Hailer et al., 2005). Due to the fact that 
NEIL2 is highly unstable and quickly loses its activity even after being stored at low 
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temperature and when incubated at 37ºC, no data has been showed for the activity of NEIL2 on 
oligonucleotide substrate with multiple oxidative lesions (Hazra et al., 2002). 
NEIL2 knockout mice show accumulation of oxidative DNA lesions with significant sensitivity 
to inflammation. The increase of oxidative DNA damage was remarked as age dependent DNA 
damage, whilst genetic instability and telomere loss has also been detected in embryonic 
fibroblasts of these knockout NEIL2 mice (Chakraborty et al., 2015).   
Multiple polymorphic variants of NEIL2 have been detected in different types of cancers: 
NEIL2-Arg257Leu and NEIL2-Arg103Gln were detected in lung cancer and have been 
overexpressed and purified (Broderick et al., 2006). NEIL2-Arg257Leu is specifically 
expressed in lung cancer cells and showed less activity and a significant increase in DNA lesion 
accumulation in comparison with NEIL2 wild type, suggesting that humans carrying this type 
of NEIL2 allele are more susceptible to developing lung cancer (Broderick et al., 2006; Dey et 
al., 2012).  
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1.8 NEIL3 
 
Figure 1.9  Human NEIL3 protein possesses FpgNei superfamily, H2TH, zinc-finger (zf-RanBP) 
and two zf-GRF zinc finger domains and consists of 606 amino acids. 
 
NEIL3 is the largest member of the NEIL family in mammalian cells consisting of 606 amino 
acids in human cells (Morland et al., 2002). The protein differs from the other NEIL paralogs 
in two main respects, firstly the canonical N-terminal proline is replaced by valine and NEIL3 
has an extended C-terminal tail that contains multiple zinc finger domains of as yet unknown 
function (Liu et al., 2002). 
Studies found that insect cell lysates overexpressing NEIL3 can excise methyl FapyG (Morland 
et al., 2002) and a weak AP lyase activity has been observed on single-stranded DNA substrates 
(Takao et al., 2010). A study on full-length mouse NEIL3 and an N-terminal DNA glycosylase 
domain truncation indicated a strong substrate preference for oxidized purines and pyrimidines 
in single-stranded DNA (Liu et al., 2010). The single-stranded DNA lesion preference of 
NEIL3 is due to its lack of two void-filling residues that stabilize the DNA duplex and interact 
with the opposite strand (Wallace et al., 2013). 
NEIL3 is expressed only in highly proliferating cells, such as those in testes, thymus and in 
cancer cell lines. Although studies have shown that NEIL3 has substrate specificity for oxidized 
pyrimidines and purines, no excision activity has been observed for 8-oxoG (Wilson & Bohr, 
2007), although in common with the other NEIL paralogs it does have a major role in removing 
the hydantoin products of 8-oxoG oxidation, Sp and Gh (Liu et al., 2010; Klattenhoff, et al., 
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2017). However, NEIL3 also has been shown to possess excision activity on various DNA 
lesions in ssDNA such as, 5-OHU, 5-OHC, 5-OH-5MeHyd and TG (Qi et al., 2009).  
The NEIL3 protein structure features an N-terminal conserved domain and a long C-terminal 
tail (Figure 1.9) that distinguishes NEIL3 from NEIL1 and NEIL2. The NEIL3 protein contains 
the Fpg/Nei catalytic domain at the N-terminus, with the replacement of proline by valine at 
position 2. Additionally NEIL3 contains the H2TH DNA binding domain of the Fpg/Nei 
superfamily, a zinc finger motif (zf-RanBP) and tandem Zn-GRF domains at the C-terminal 
(Figure 1.9). The function of the C-terminal domains of NEIL3 is still unknown and is subject 
of continued research (Krokeide et al., 2009; Krokeide et al., 2013). 
G-quadruplex DNA structures have been found in telomeric DNA and the promoters of several 
genes in eukaryotic chromosomes (Zhou et al., 2013). The G-quadruplex DNA structure has 
been found to be susceptible to oxidative DNA damage producing, 8-oxoG, Sp, Gh and TG 
lesions (Zhou et al., 2013). Therefore, the activity of DNA glycosylases has been tested on G-
quadruplex substrates (Zhou et al., 2015). Thus, a recombinant NEIL3 protein from Mus 
musculus showed excision activity on TG in quadruplex DNA while NEIL1 from the same 
source exhibited a preference for Sp and Gh lesions, suggesting that NEIL3 and NEIL1 shared 
a DNA repair role for damaged bases in telomeres and G-quadruplex DNA (Zhou et al., 2013). 
Therefore, NEIl3 has a preference in vitro for single-stranded DNA substrates and quadruplex 
DNA structures in comparison to double-stranded DNA (Krokeide et al., 2009; Liu et al., 2010, 
2012; Zhou et al., 2013). This substrate preference has been suggested to be one possible 
function of the extended C-terminal domains of NEIL3 (Liu et al., 2010). 
The expression of NEIL3 in highly proliferating cells during the S-and G2-phase of the cell 
cycle makes NEIL3 an interesting target to investigate its role in the repair of oxidative damage 
in telomeres. Telomeres are DNA structures covering the end of mammalian chromosomes and 
are guanine rich DNA structures and thus more susceptible to oxidative damage by ROS. The 
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telomeric repeat proteins TRF1, TRF2 and POT1 act as a shield to protect (shelter) telomeres 
from the DNA damage response. (Palm and de Lange, 2008). Because telomeres are more 
sensitive to oxidative damage in vitro or in vivo due to G-rich components (Hewitt et al., 2012; 
Wang et al., 2010), unrepaired DNA lesions in telomeres may affect the binding of the 
protecting telomeric proteins and lead to telomere defects that can trigger apoptosis or  more 
significantly are linked to some types of cancer such as, colon, prostate and breast in which 
chromosomal instability is characterised (Chin et al., 2004; Meeker et al., 2002; Rudolph et al., 
2001). 
An extensive study by Zhou et al. (2017) showed that NEIL3 has a crucial role in safeguarding 
telomere integrity against oxidative damage in highly proliferating cells, The study shows 
evidence that knockdown of NEIL3 in those cells leads to telomeric dysfunction, DNA bridges 
and ultimately cell apoptosis, suggesting a mechanism of action where NEIL3 is recruited to 
the telomeres utilizing its C-terminal domain which interacts with the TRFH domain of the 
telomeric protein TRF1 during the upregulation of NEIL3 in the cell cycle (late S/G2 phase). 
NEIL3 recognizes oxidative damage in telomeres and initiates BER by recruiting the long-patch 
BER proteins, APE1, FEN1 and PCNA. The interaction between NEIL3 and TRF1 can reduce 
double-strand breaks and thus prevent telomere fusion (Zhou et al., 2017). Protein - protein 
interactions were also detected between NEIL3 and FEN1 and PCNA, while no interaction was 
observed between NEIL3 and Polβ, suggesting that long-patch BER is the preferred mode of 
BER in telomeric regions (Zhou et al., 2017). When NEIL3 interaction with APE1 was tested, 
it was found that both a truncated version of NEIL3, consisting of the Fpg/Nei and H2TH 
domains, and the full-length NEIL3 protein interacted with APE1. However, interestingly, the 
full-length protein showed stronger interactions in comparison with the truncated NEIL3 
protein, suggesting a protein-protein interaction function for the C-terminal domain of NEIL3 
(Zhou et al., 2017). In support of these findings, NEIL3 knockdown cells show characteristics 
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of telomeric dysfunction leading to mitotic defects in highly proliferating cell types, where 
NEIL3 is overexpressed.  Thus, depletion of NEIL3 may impair telomere integrity ultimately 
leading to cell apoptosis, suggesting that NEIL3 could be an interesting target for novel 
anticancer drugs (Zhou et al., 2017).  
The catalytic domain of NEIL3 possesses a flexible DNA binding pocket that can accommodate 
a wide range of oxidized bases. This feature is utilized when NEIL3 recognizes and initiates 
BER in different shapes of telomeres. (Liu et al., 2010, 2013). 
In a study by Massaad et al. (2016), the effect of a naturally occurring human mutation in the 
N-terminal DNA glycosylase domain of NEIL3 was described. The D132V missense mutation 
ablated DNA glycosylase activity and in some instances led to increased autoimmunity, 
frequent infections and impaired B cell function in the affected individuals. In the same article, 
studies on NEIL3 knockout mice showed a significant increase in cell death by apoptosis of T 
and B cells from the spleen and also germinal centre B cells in comparison to wildtype mice. 
This led the authors to conclude that a lack of NEIL3 can lead to increased lymphocyte cell 
death and a predisposition to autoimmunity, indicating a role for NEIL3 in immune function 
(Massaad et al., 2016). 
 
1.8.1 NEIL3 in biology 
To investigate the role of NEIL3 in neurogenesis throughout brain development in the embryo, 
the NEIL3 expression pattern was followed during brain development in mice (Hildrestrand et 
al., 2009). Using quantitative PCR, the study showed elevated levels of NEIL3 expression 
corresponding to the start of neurogenesis in the developing mouse embryo. In situ 
hybridization confirmed that NEIL3 expression was specifically in areas where neural stem and 
progenitor cells are found. NEIL3 expression levels declined as the brain developed and on 
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reaching adulthood, NEIL3 was undetectable by quantitative PCR (Hildrestrand et al., 2009). 
However, using NEIL3 knockout mice, it was reported that NEIL3 is essential for the 
maintenance of neurogenesis in adult mice that NEIL3 is required for the repair of oxidative 
DNA damage in neural stem/progenitor cells to prevent age-associated neurodegeneration and 
deterioration of cognitive function (Regnell, et al., 2012). In relation to this, NEIL3 has also 
been shown to be involved in the recovery of neurogenesis following hypoxia-ischemia in a 
mouse model (Sejersted et al., 2011). 
Skarpengland et al. (2015) used a nested case-control study to investigate the role of several 
BER proteins in the risk of myocardial infarction as increased ROS and oxidative DNA damage 
are known to be contributing factors in atherosclerosis. Of the BER genes studied, only a SNP 
in NEIL3 (rs12645561TT) was associated with an increased risk of myocardial infarction. Thus, 
the authors concluded that decreased NEIL3 expression or activity, may result in increased 
atherogenesis and increased risk of heart disease (Skarpengland et al., 2015).  
1.9 DNA crosslinks 
Inter-strand crosslinks (ICLs) accrue in cells due to the formation of covalent bonds between 
bases on the two strands of the DNA molecule. ICLs can either be induced by natural products 
of metabolism or by exogenous chemical agents, most notably those used in cancer 
chemotherapy Most common ICL - inducing chemotherapeutic agents are classified into four 
main groups, (i) alkylating agents, (ii) platinum – based agents such as cisplatin, carboplatin 
and oxaliplatin, (iii) nitrogen mustards such as cyclophosphamide and chlorambucil, and (iv) 
other compounds such as mitomycin C and psoralen (Deans and West, 2011). 
ICL - inducing agents act mostly in similar manner utilizing two active leaving groups in order 
to activate the drug, the bifunctional platinum and nitrogen mustards react with guanine or 
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adenine bases in the two strands of the double helix at the N7 position by consecutive 
replacement of two chloride ions with two water molecules (Figure 1.10). 
 
 
 
 
 
 
 
Figure 1.10 Cisplatin and Nitrogen mustard inducing ICLs DNA lesions (taken from Deans and 
West, 2011)  
 
Psoralen, on the other hand, reacts through photon mediated cycloaddition, resulting in cross-
linked thymidine nucleotides, while photon mediated cycloreduction of mitomycin C causes 
crosslinking between guanine bases on the opposite strands. Psoralen is widely used in the 
treatment of the skin condition, psoriasis, in conjunction with UVA treatment (Figure 1.11; 
Deans and West, 2011). 
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Figure 1.11 Photoactivation reaction and intracellular reduction reaction effect on thymine and 
guanine generating crosslinked thymine and crosslinked guanines respectively (taken from 
Deans and West, 2011)  
 
Chemical agents introducing ICLs are used as anticancer treatments, due to the toxicity of the 
ICL that prevent transcription, and stall DNA replication of cells and if unrepaired could trigger 
cell death (Martin et al., 2017). 
In mammalian cells, ICLs are repaired by DNA repair machineries the incising strand at either 
side of the ICLs leaving a gap which filled by homologous recombination then the repair is 
completed by nucleotide excision repair (NER). While in eukaryotic multiple DNA repair 
mechanisms are involved; NER, homologous recombination, BER and the Fanconi anaemia 
proteins, the efficiency of the repair in order to maintain the genome integrity is dependent on 
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retrieving the missing information (DNA sequences) from an undamaged homologous 
chromosome (Deans and West, 2011).   
1.9.1 NEIL3 in DNA crosslink repair 
Human NEIL3 proved to be active on DNA crosslinks induced by psoralen on both three and 
four-stranded DNA structures leaving unhooked DNA products (Martin et al., 2017). NEIL3 
acts on both DNA strands of the four stranded ICL while Nei and NEIL1 cleave psoralen four 
stranded crosslinks DNA substrates leaving two double-stranded DNA with nick. NEIL3 cleave 
the psoralen ICL three and four-stranded DNA structures with no resultant single-strand breaks. 
The three and four-stranded ICL DNA can be formed in vivo during replication from replication 
forks where NEIL3 is upregulated and expressed in highly proliferating cells suggesting a role 
for NEIL3 in the repair of replication fork (Martin et al., 2017).  The study shows evidence that 
Nei, NEIL1 and NEIL3 repair three and four-stranded ICL DNA structures induced by psoralen 
by unhooking the substrates, hydrolysing the glycosylic bond between the oxidized base and 
the sugar backbone of the DNA with no resultant double-strand breaks (Martin et al., 2017). 
The three and four-stranded ICL DNA structures can be formed during DNA replication, 
supporting the suggestion that Nei-like DNA glycosylases, Nei, NEIL1 and NEIL3 have a role 
in DNA repair at the replication fork, and furthermore, that this function is conserved from E. 
coli to human cells. 
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1.10  hNEIL3 Expression vectors 
1.10.1 pET30a-ORF6: 
The pET30a-ORF6 vector was constructed by Guo et al (2009) in an attempt to express the 
Rv3297 gene (MtuNei2) in E. coli. Previous attempts to express the Rv3297 gene in E. coli, 
based on the theory that the rare codons are the major factor in insufficient protein expression, 
were not successful to produce a significant amount of the protein either by augmenting tRNAs 
for rare codons or amplifying the gene with preferred codons for E. coli (Guo et al., 2009). 
Instead, the study proved that the formation of secondary structures surrounding the translation 
initiation region was the main factor affecting translation and protein expression. The vector 
proved efficienct for expressing proteins from G/C rich organisms and carry a proline residue 
at the N-terminus (Guo et al., 2009). 
The vector is called bicistronic because it possesses two cistrons, an upstream cistron (ORF6) 
which is 74 nucleotides long and reduces the local secondary structures in the mRNA which 
surround the translation initiation region allowing efficient translation initiation, and a 
downstream cistron that accommodates the target gene. The coupled translation mechanism has 
been anticipated in two patterns, one is that the secondary structures which inhibit translation 
of the downstream cistron is disturbed by the ribosome translating the upstream cistron resulting 
in other ribosomes ability to reach the ribosome binding site of the downstream cistron thus 
starting the translation of the coupled downstream gene. The other pattern is that the ribosome 
translating the upstream cistron is able to re-initiate translation for the downstream cistron.   
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1.10.2 pETDuet-2 bicistronic expression vector 
In NEIL3 protein expression in E. coli, the removal of N-formylmethionine is required for the 
catalytic activity of the protein. The process is divided into two steps; one is the release the 
formyl group by a peptide deformylase which is coupled to translation, the other is N-terminal 
methionine cleavage by an amino peptidase (Liu et al, 2012). 
N-terminal methionine processing is dependent on the amino acids in the second and third 
position of the target protein. It has been shown that valine at the penultimate (second position) 
and glutamic acid residues at the antepenultimate (third position) in the translated protein results 
in incomplete processing of the N-terminal methionine in E. coli (Frottin et al., 2006). An 
engineered EcoMap (EcoMapY168A) from pBSMap (Y168A)-cGSTM produced promising 
results of processing the N-terminal methionine in proteins with valine residue at penultimate 
position (Liu et al., 2012).  
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1.10.3 Construction of the bicistronic vector pETDuet-2-T7EcoMap-ORF6 
Liu and colleagues (2012) modified the pETDuet-1 expression vector (Novagen) by amplifying 
a mutated version of the E. coli amino peptidase, EcoMapY168A, then the PCR product was 
digested and ligated into the pETDuet-1 using NcoI and SalI restriction enzymes resulting 
pETDuet-1-T7 EcoMapY168A (Liu et al., 2012). Then the leader sequence ORF6 and hexa-
histidine tag from previous pET30a-ORF6 vector were cloned into the vector using NdeI and 
StyI cut in the T7 terminator. The target protein mouse NEIL3 was cloned into the NdeI and 
XhoI cut in ORF6 leader sequence resulting of pETDuet-2-T7EcoMap-ORF6-NEIL3 
expression vector (Figure 1.12). The expression of active recombinant MmNeil3 and N-
terminal hNEIL3 using the pETDuet-2-EcoMap-ORF6 expression vector was successful with 
DNA glycosylase/lyase activity when was subjected to substrates containing Sp and thymine 
glycol (TG), or an AP site in single- and double-stranded DNA (Liu et al., 2012).  
 
 
 
 
 
 
 
 
Figure 1.12 Map of the pET30a and pETDuet-2 expression vectors containing murine NEIL3.  
The figure shows the position of the ORF6 and EcoMap Y168A, the His-Tag and the restriction 
sites that were used to construct the vector (taken from Liu et al, 2012). 
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1.11  Project aims and objectives 
The biochemical properties of NEIL3 are still an enigma and due to the fact that the protein is 
highly expressed in cancer cells, testing the function of the protein domains to determine which 
of the domains is responsible for the protein activity could lead to therapeutic significance.  In 
this regard, studies have demonstrated that cells from mice were lacking NEIL3 show 
sensitivity to oxidative genotoxins and the DNA cross-link inducing agent, cisplatin (Rolseth, 
et al., 2013).  
In this project expression and purification of full-length and four truncated versions of hNEIL3 
was undertaken to test the effect of the five protein domains of human NEIL3 (hNEIL3) on 
DNA damage substrates to further characterize the biochemical properties of hNEIL3. Thus, 
expression and purification of hNEIL3 full-length and four truncated versions was attempted to 
test the effect of the different  protein domains on DNA glycosylase / AP lyase activity (Figure 
1.13). 
 
 
 
 
 
 
 
Figure 1.13 Conserved protein domains of E. coli Nei, M. musculus NEIL3 (MmNEIL3) and 
hNEIL3. 
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Figure 1.14 Illustration of hNEIL3 protein shows the site of the different truncations in relation 
to the conserved protein domains of hNEIL3. 
The figure shows the hNEIL3 protein domains and their positions. Numbers refer to the 
nucleotide position in the cDNA (CDS). 
 
The first stage of the project entailed that full-length hNEIL3 and four truncated versions 
(Figure 1.14) were cloned in to pET30b-ORF6. Thereafter, the ORF6-hNEIL3 (or truncated 
hNEIL3 cDNA) was released from the vector and introduced to the pETDuet-2 bicistronic 
expression vector and this used to transform E. coli cells and tested for protein expression. The 
resulting His-tagged proteins were purified by chelation and ion-exchange chromatography and 
biochemical enzyme assays performed to determine the effect, if any, of the C-terminal domains 
on DNA glycosylase / AP lyase activity. 
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2 Materials 
 
 
Table 2.1 Materials used in molecular cloning experiments 
 
 
 
 
 
 
 
 
Material Description 
Tris-Borate-EDTA 
(TBE) 
5x TBE was prepared by dissolving 54 g of Tris base, 27.5 g of 
boric acid and 20 ml of 0.5 M EDTA pH8.0 in 1 L of dH2O. The 
5x TBE stock solutions was diluted 10 fold to 0.5 x prior to use. 
Agarose Gel 
Electrophoresis 
Loading Buffer 
4 g of sucrose, 25 mg of bromophenol blue (0.25% w/v), and 2.4 
ml of 0.5 M EDTA pH 8.0 was mixed and made up to 10 ml with 
dH2O. 
DNA Size Marker 
1 µl of Hyperladder 1kb (Bioline) was used to determine DNA 
band sizes for all agarose electrophoresis experiments. 
GelRed  
4 μl of GelRed (Biotium) was added to 100 ml of agarose gel 
solution at approximately 50ºC. 
Lysogeny broth (LB) 
5 g of LB-broth powder (Sigma-Aldrich) was added to 200 ml of 
dH2O followed by autoclaving at 121°C for 45 min.  
LB with agar 
LB with agar (Sigma-Aldrich) was prepared by adding 7 g of LB- 
agar powder to 200 ml of dH2O followed by autoclaving at 121°C 
for 45 min.  
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2.1 Protein Expression and Purification Materials 
 
Table 2.2  Materials used in Recombinant Protein Expression, Purification and Analysis. 
Material Description 
Acrylamide  Acrylamide (30% acrylamide, 0.8% bis) obtained ready 
for use (Bio-Rad). 
Ammonium Persulfate (APS)  A 10% (w/v) stock solution of APS was prepared by 
dissolving 1 g of APS in 10 ml dH2O. Aliquots were 
stored at -20°C. 
Tetramethylethylenediamine 
(TEMED) 
TEMED was obtained from Sigma-Aldrich. 
 
 
 
SDS-PAGE Loading Buffer (3x) 
 
The stock was prepared by mixing, 2.4 ml of 1M Tris-
HCl pH 6.8, 3 ml 20% (w/v) SDS, 3 ml, 100% (v/v) 
glycerol, 1.6 µl 2-mercaptoethanol and 6 mg 
bromophenol blue and the final volume adjusted to 10 ml 
with dH2O and stored at 4°C. 
 
 
SDS-PAGE Running Buffer 10x 
The 10x stock was prepared by mixing 30.2 g Tris base, 
10 g of SDS and 144 g of glycine in about 900 ml of 
H2O. The pH was adjusted to pH8.3 if required and the 
volume adjusted to 1 L with dH2O. The 10x stock was 
diluted to 1x buffer just before use. 
SDS-PAGE stacking gel buffer 0.5M Tris-HCl pH6.8, 10% (w/v) SDS 
SDS-PAGE separating gel buffer 1.5M Tris–HCl pH 8.8, 10% (w/v) SDS   
 
 
Western Blot Transfer Buffer 
(WTB) 
 
10x western blot transfer buffer (WTB) was prepared by 
dissolving 144 g glycine and 30.2 g Tris base and the 
final volume made up to 1 L with dH2O. A 1x working 
buffer was prepared by adding 100 ml of 10x TG to 200 
ml of methanol and made up to 1 L with dH2O and stored 
at 4°C. 
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Phosphate Buffered Saline (PBS) 
Stock Solution (10x) 
10x PBS was prepared by adding 80 g NaCl, 2 g KCl, 
7.62 g Na2HPO4 and 0.77 g KH2PO4 to 800 ml of dH2O. 
Once fully dissolved, the pH was adjusted to pH7.4 with 
concentrated HCl and the total volume made up to 1 L 
with dH2O. 
PBS-Tween-20 
 
The working solution of PBS-Tween-20 contained 100 
ml of 10x PBS and 1 ml of Tween-20 made up to 1 L 
with dH2O. 
 
Blocking buffer Blocking buffer was prepared using Odyssey blocker 
solution (LI-COR) diluted 1:1 in 1x PBS. 
 
Antibody dilution buffer The antibody dilution buffer was prepared using 
Odyssey blocker solution (LI-COR) diluted 1:1 in 1x 
PBS containing 0.1% Tween-20. 
Protein molecular weight (MW) 
Standards  
Precision plus protein All Blue Pre-stained Protein 
Standards (Bio-Rad) were used to determine the 
molecular weight of polypeptides following SDS-PAGE 
and western blotting.  
IPTG (Isopropyl β-D-1-
thiogalactopyranoside) Stock 
Solution 
 
IPTG stock solution was prepared to a final 
concentration of 100 mM by dissolving 120 mg of IPTG 
powder (Promega) in 5 ml dH2O then filter sterilized and 
stored at -20°C. 
 
Bacterial pellet Lysis Buffer 
 
 
 
Bacterial lysis buffer was prepared by mixing 25 mM 
Tris-HCl pH 8.0, 500 mM NaCl, 5% (v/v) glycerol and 
5 mM imidazole then dH2O to a final volume of 500 ml.  
To each 30 ml, 30 µl of protease inhibitor cocktail; 
(leupeptin, pepstatin a, chemostatin, and aprotinin, 
Thermo Fisher Scientific) and 100 µl of 100 mM 
Phenylmethane sulphonyl fluoride (PMSF; Sigma-
Aldrich) was added just before use. 
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FPLC His-Trap purification 
buffers 
 
Buffer A consisted of: 25 mM Tris-HCl pH 8.0, 500 mM 
NaCl, 5% (v/v) glycerol, 5 mM imidazole and 0.1 mM 
PMSF. 
Buffer B consisted of: 25 mM Tris-HCl pH 8.0, 500 mM 
NaCl, 5% (v/v) glycerol, 500 mM imidazole and 0.1 mM 
PMSF. 
 
FPLC Mono S purification 
buffers 
 
Buffer A consisted of: 50 mM Tris-HCl pH 8.0, 50 mM 
KCl, 1 mM EDTA pH8.0, 5% (v/v) glycerol, 1 mM 
dithiothreitol (DTT) (1:1000 dilution from 1 M stock) 
and 0.1 mM PMSF. 
Buffer B consisted of: 50 mM Tris- HCl pH 8.0, 1 M 
KCl, 1 mM EDTA pH8.0, 5% (v/v) glycerol, 1 mM DTT 
and 0.1 mM PMSF. 
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2.2 Activity Assay Materials 
 
Table 2.3 Materials used in Recombinant Protein Activity Assays  
 
2.2.1 Oligonucleotide Substrates 
The sequences and design of the oligonucleotides used in the activity assays is given in Table 
2.4. The oligonucleotides containing the modified base were fluorescently labelled with 5ʹ-
IRDye700 (8-oxoG, TG, U) or 5ʹ-Alexa Fluor 680 (5-OHU) and were purchased from IDT 
Technologies. Double-stranded oligonucleotides and mock replication fork substrates were 
produced by adding a 1.5-fold excess of the complementary oligonucleotide, heating at 95°C 
for 5 min and then left to cool at room temperature.  
 
 
 
 
 
 
Material Description 
Denaturing -
PAGE sample 
loading buffer 
95% (v/v) formamide, 0.02% (w/v) xylene cyanol, and 0.02% (w/v) 
bromophenol blue. 
 
Activity assay 
reaction buffer 
The activity assays were carried out using 300 nM of purified proteins 
and 5 nM of the substrate oligonucleotides in a total volume of 10 µL of 
reaction mixture containing, 50 mM Tris-HCl pH 7.8, 50 mM KCl, 10 
mM MgCl2, 0.5 mM EDTA pH8.0, 1.5 mM DTT, 8.5% (v/v) glycerol, 
and 100 µg/ml bovine serum albumin (BSA). 
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Table 2.4  Oligonucleotide Substrate Design and Sequences. 
Substrate Oligonucleotide sequence and construct design 
 
Single-stranded DNA substrate 
5'-ATCTACCGAGTCCGTCCGAXCACGCTTATTGGCTACCGA-3' 
 
 
 
X denotes the position of the base modification (5-OHU / 8-oxoG / 
TG). 
 
Double-stranded DNA 
substrate 
5ʹ-ATCTACCGAGTCCGTCCGAXCACGCTTATTGGCTACCGA-3ʹ 
3ʹ-TAGATGGCTCAGGCAGGCT1GTGCGAATAACCGATGGCT-5ʹ 
 
 
 
X denotes the position of the base modification (5-OHU / 8-oxoG / 
TG), while ‘1’ represents the appropriate complementary base 
opposite the oxidised base. 
 
 
Fork -4 DNA substrate 
 
5ʹ -ATCTACCGAGTCCGTCCGAXCACGCTTATTGGCTACCGA-3' 
3ʹ-TAGATGGCTCAGGCAGCTATAGCTACCGCCTTACGTAAG-5ʹ 
 
 
 
 
 
 
 
X denotes the position of the base modification, 5-OHU, 8-oxoG or 
TG. 
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Fork DNA substrate 
 
5ʹ-ATCTACCGAGTCCGTCCGAXCACGCTTATTGGCTACCGA-3ʹ 
3ʹ-TAGATGGCTCAGGCAGGCT1AGCTACCGCCTTACGTAAG -5ʹ 
 
 
X denotes the position of the base modification (5-OHU / 8-oxoG / 
TG), while ‘1’ represents the appropriate complementary base 
opposite the oxidised base. 
 
 
Fork +4 DNA substrate 
 
 5ʹ-ATCTACCGAGTCCGTCCGAXCACGCTTATTGGCTACCGA-3ʹ 
 3ʹ-TAGATGGCTCAGGCAGGCT1GTGCACCGCCTTACGTAAG-5ʹ 
 
X denotes the position of the base modification (5-OHU / 8-oxoG / 
TG), while ‘1’ represents the appropriate complementary base 
opposite the oxidised base. 
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3 Methods 
3.1 Cloning Methods 
3.1.1 Bacterial Culture  
For both LB and LB with agar, the selection antibiotic was added after autoclaving and cooling 
to approximately 50°C. The LB-agar was poured into 10 cm petri dishes, left to set and the 
plates stored at 4°C until needed, while the LB was stored at room temperature. E. coli bacterial 
overnight cultures were prepared in 5 ml of LB in universal tubes and 5 μl of ampicillin (100 
mg/ml) or 5 μl of kanamycin (30 mg/ml) was added where appropriate, just before the addition 
of the E. coli cells. The tubes were incubated overnight (16 - 18 h) at 37°C in a shaking incubator 
at 220 rpm.  
3.1.2 Plasmid DNA Extraction and Quantification 
Plasmid DNA extractions were carried out as described in the Isolate II Plasmid mini kit 
protocol (Bioline). Three millilitres of overnight culture were centrifuged for 30 s at 11,000 xg, 
the supernatant discarded and the pellet re-suspended in 250μl re-suspension Buffer P with 
vortexing. Then 250 μl of Lysis Buffer P2 was added and mixed by inversion and incubated for 
5 min at room temperature. Then 300 μl of Neutralization Buffer P3 was added, mixed 
thoroughly by inversion and centrifuged for 5 min at 11,000 xg. An Isolate II Plasmid Mini 
Spin Column was placed in a 2 ml collection tube and the clarified supernatant was pipetted 
into the column and centrifuged for 1 min at 11,000 xg. The flow-through was discarded and 
500 μl wash buffer PW1 was added to the column to wash the silica membrane and centrifuged 
for 1 min at 11,000 xg after which the flow-through was discarded and 600 μl of wash buffer 
PW2 was added and the column centrifuged again for 1 min at 11,000 xg. The flow-through 
was discarded and the column dried by centrifuging for 2 min at 11,000 xg. Finally, the column 
was placed into a fresh 1.5 ml collection tube and 50 μl of Elution Buffer P was added onto the 
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column, incubated at room temperature for 1 min and then centrifuged for 1 min at 11,000 xg. 
The flow-through was collected and the plasmid DNA concentration measured using a 
NanoDrop 2000 instrument (Thermo Scientific) and stored at -20°C. 
3.1.3 Agarose Gel Preparation 
Agarose gels were prepared by dissolving 0.8 g of agarose (Fisher BioReagents) in 100 ml of 
0.5x TBE by heating in a microwave and then the mixture left to cool to approximately 50°C 
and 4 μl of GelRed (Biotium) was added. The liquid agarose was then poured into a gel tray, a 
well-forming comb placed in position and the gel left at room temperature to set. The gel was 
then placed in an electrophoresis tank containing 0.5x TBE and the comb removed. 
3.1.4 Polymerase Chain Reaction (PCR) 
PCR was used to amplify the target hNEIL3 cDNA from pCMV6-AC-hNEIL3 (OriGene) for 
use in molecular cloning. Details of the PCR primers used are given in Table 2.2 with the XhoI 
site and three flanking nucleotides underlined. 
 
Table 3.1 PCR Primers for hNEIL3. 
Primer Primer sequence Tm 
Tm (XhoI site 
included) 
CG% 
hNEIL3 Fwd. 
G GTG GAA GGA CCA GGC TGT 
ACT CTG AAT 
73.2°C — 53.6 
hNEIL3 843 bp 
Rev 
CCG CTC GAG TTT TTG  ACA 
GTG AGG ACA GAA ATA TGT 
CAT TCT GT 
72.1°C 79.8°C 34.3 
hNEIL3 1044 bp 
Rev 
CCG CTC GAG TGA ATC AAT 
AGG CCT TGA GGT CAA GC 
70.7°C 80.7°C 46.2 
hNEIL3 1236 bp 
Rev 
CCG CTC GAG ATC TAG TAT 
CTG GTT TTG CTT TGT TTT TCT 
TTC CAA AG 
71.9°C 81.1°C 31.6 
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PCR reaction mixtures for hNEIL3-full length and reaction conditions were as follows: 
 
PCR reaction mix for full length hNEIL3 cDNA 
Reagent                                                           Amount 
1 ng/µl Template DNA                           1.5 µl 
5x Reaction buffer                         10.0 µl 
10 mM dNTPs                            1.0 µl 
10 µM Forward primer                           2.5 µl 
10 µM Reverse primer                           2.5 µl 
DMSO                             1.5 µl 
Phusion DNA polymerase (NEB)                        0.5 µl 
dH2O                           30.5 µl 
Total                           50.0 µl  
 
  PCR Cycle Conditions 
95°C  30 s 
95°C  10 s 
76°C  30 s 
72°C  30 s 
72°C  10 min 
4°C  Hold  
hNEIL3 1506 bp 
Rev 
CCG CTC GAG AGG ATT TAA 
GGT ACG AGG GCC ATC TGT 
70.4°C 81.5°C 48.1 
hNEIL3 Full 
length Rev 
CCG CTC GAG GCA TCC AGG 
AAT AAT TTT TAT TCC TGG CC 
71.9°C 82.2°C 41.4 
Sense ORF6-
hNEIL3 Fwd.   
TATGAAAATCGAAGCAGGTAA
ACTGGTACAGAAGG 
67.1°C —  40 
30 cycles 
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For preparation of the four truncated cDNAs, the reaction mixtures and PCR reaction conditions 
were as follows: 
 
PCR reaction mix for truncated hNEIL3 cDNAs 
Reagent                                                        Amount 
10 ng/µl template DNA                           1.5 µl 
5x Reaction buffer                          10.0 µl 
10 mM dNTPs                 1.0 µl 
10 µM Forward primer                2.5 µl 
10 µM Reverse primer                2.5 µl 
Phusion DNA polymerase                           0.5 µl 
dH2O                            32.0 µl 
Total                            50.0 µl 
 
PCR Cycle Conditions 
95°C  30 s 
95°C  10 s 
76°C  30 s 
72°C  30 s 
72°C  10 min 
4°C  Hold 
 
  
30 cycles 
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3.1.5 Restriction Endonuclease Digests 
All restriction endonuclease digests were carried out using 300 ng of plasmid DNA, 10 units of 
restriction enzyme and the appropriate buffer according to the manufacturer’s recommendation 
(New England Biolabs). 
 
Table 3.2 Restriction Endonuclease Digest Reaction Mixture 
 
Component volume 
Plasmid cDNA (~300 ng)   5.0 µl 
10x NEB Buffer   2.0 µl 
Enzyme (20 units/µl)   0.5 µl 
dH2O 12.5 µl 
Total 20.0 µl 
 
Reactions were carried out at 37°C for 1 h. 
 
3.1.6 DNA Ligation 
All DNA ligation reactions were carried out using T4 DNA ligase (New England Biolabs). The 
protocol was as follows: 
The amount of insert DNA required was calculated using the following formula to achieve a 
3:1 insert/vector ratio: 
X ng insert =           (y bp insert) (z ng vector) 
                                                      bp of vector 
 
In general, 50 ng of vector was used in the DNA ligation reactions. 
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Table 3.3 Reaction mix for ligation of hNEIL3 inserts into (pET30b-ORF6 and pETDuet-2) using 
T4 DNA ligase. 
 
Reagent Volume 
10x T4 DNA ligase Buffer 2µl 
Vector DNA (50 ng) x µl 
Insert DNA x µl 
Nuclease-free water Up to 20 μl 
Total 20 μl 
 
Reactions were carried out at 16°C for approximately 18 h. 
 
3.1.7 Mung Bean Nuclease 
Blunting of the plasmid DNA fragment by degrading the 5ʹ overhang resulting from NdeI 
digestion was carried out using mung bean nuclease (New England Biolabs). The reaction 
mixture contained 5 µl of 1x mung bean nuclease reaction buffer and 1 µl (10 units) of mung 
bean nuclease. The reaction was incubated at 30°C for 30 min. 
 
3.1.8 Clean-up and Purification from an Agarose Gel of DNA Fragments. 
Digested plasmids and inserts were cleaned up using an Isolate II PCR and Gel Kit (Bioline). 
The sample was prepared by mixing 1 volume of sample with 2 volumes of Binding Buffer CB. 
Then an Isolate II PCR and Gel Column were placed into a 2 ml collection tube and the sample 
loaded into the column and centrifuged for 30 s at 11,000 xg. The flow-through was discarded 
and the silica membrane of the column was washed by adding 700 μl Wash Buffer CW to the 
column and centrifuged for another 30 s at 11,000 xg. The flow-through was discarded and the 
column placed back into the collection tube and the silica membrane dried by centrifuging for 
1 min at 11,000 xg. The spin column was then placed in a fresh 1.5 ml tube and 15 - 30 μl of 
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Elution Buffer C was added directly onto the silica membrane, incubated at room temperature 
for 1 min, and centrifuged again for 1 min at 11,000 xg. The DNA was collected and the 
concentration measured using a Nano Drop 2000 instrument (Thermo Scientific) and stored at 
-20°C.   
 
3.1.9 Transformation of E. coli NovaBlue competent cells 
NovaBlue and Rosetta 2 competent E. coli cells (Novagen) were kept at -80°C in tubes of 20 
μl. The cells were thawed on ice for two to five minutes and then were finger-flicked to ensure 
complete re-suspension. One microlitre of a ligation reaction was added to each tube separately, 
mixed gently, put on ice and incubated for 5 min. Then the cells were heat-shocked at 42°C for 
exactly 30 s and returned to ice for 2 min. Eighty microlitres of SOC medium (2% tryptone, 
0.5% yeast extract, 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl2, 10 mM MgSO4, and 20 mM 
glucose) was added to each tube and either incubated at 37°C in a shaking incubator for 30 
minutes, if the selection antibiotic was kanamycin, or spread directly on LB-agar (+antibiotic) 
plates. The plates were then incubated in a 37°C incubator overnight.  
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3.2 Protein expression and purification methods 
3.2.1 Protein expression (test cultures) 
A single bacterial colony was transferred to 3 ml of LB with ampicillin (50 µg/ml) and 
chloramphenicol (34 µg/ml) and incubated at 37°C with shaking until an OD600nm of ~ 0.6-0.8 
was reached and then stored at 4°C. (A glycerol stock was also made by removing 150 µl of 
culture, and adding 50 µl 50% (v/v) glycerol then stored at -80°C to create a frozen stock.) 
Three hundred microlitres of this culture was used to start two 30 ml cultures (1:100) containing 
antibiotics (30 μl ampicillin (50 mg/ml) and 30 µl chloramphenicol (34 mg/ml)) plus 60 µl 20% 
(w/v) glucose. A 1 ml aliquot was removed, centrifuged for 1 min at 13,000 xg, the supernatant 
discarded and the pellet stored at -80°C (un-induced control). Then the 30 ml cultures were 
incubated with shaking at 37°C until an OD600nm ~ 0.8-1.0 was obtained. 
The cultures were induced with 30 µl 1 M IPTG (final concentration 1 mM) and grown 
overnight at 37°C (or 16°C) with shaking. Aliquots of 1 ml were removed at 1 h, 3 h, and 
overnight post-induction, centrifuged for 1 min at 13,000 xg, the supernatant removed and 
pellets stored at -80°C. The remaining ~30 ml culture was centrifuged at 8,000 xg for 10 min, 
the supernatant was removed and the pellet stored at -80°C. 
The cell pellets obtained from the 1 ml aliquots (un-induced control, plus 1 h, 3 h and overnight 
pellets at 37°C and 16°C) were re-suspended in 200 µl 1x SDS loading buffer) then carefully 
sonicated using 3 x 15 s bursts with 30 s intervals on ice. Then samples were heated to 95°C 
for 5 minutes to be analysed by SDS-PAGE and western blotting. 
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3.2.2 Protein expression for subsequence purification 
Three millilitre LB cultures were prepared from the bacterial glycerol stock with the 
corresponding antibiotics (3 μl ampicillin (50 mg/ml)) and 3 µl chloramphenicol (34 mg/ml)) 
and incubated at 37°C with shaking. The cultures were grown until an OD600nm of ~ 0.6 - 0.8 
was obtained and then stored at 4°C. The following day, 300 µl of culture was used to seed two 
30 ml cultures (1:100) containing antibiotics (30 μl ampicillin (50 mg/ml) and 30 µl 
chloramphenicol (34 mg/ml)) plus 60 µl 20% (w/v) glucose. Then the 30 ml cultures were 
grown at 37°C with shaking until an OD600nm of ~ 0.8 - 1.0 was reached. This was used to seed 
a 300 ml culture (1:10) containing 300 μl ampicillin (50 mg/ml) and 600 µl 20% (w/v) glucose 
and incubation was continued until an OD600nm of ~ 0.8 - 1.0 was obtained. The cultures were 
then induced with 1 mM IPTG (330 µl of 1 M stock) and incubated overnight at 20°C with 
shaking. The culture was centrifuged at 8,000 xg for 10 min, the supernatant discarded and the 
pellets stored at -80°C for subsequent purification. 
 
3.2.3 Protein purification (His-Trap FPLC) 
The bacterial pellets were re-suspended in 30 ml of lysis buffer supplemented with 30 μl of 
protease inhibitor cocktail (all at a concentration of 1 mg/ml) and 100 μl of 100 mM PMSF. 
Then, 0.1 mg/ml lysozyme was added and the mix was incubated on ice for 15 min. Cells were 
lysed by sonication on ice using 3 x 15 s bursts at 30 s intervals and centrifuged in Oakridge 
tubes at 25,000 xg for 20 min at 4°C. The supernatant was collected and filtered through 1 µm 
syringe pre-filters, and then through 0.45 µm syringe filters. A 1 ml His-Trap column (GE 
Healthcare) was washed with 3 volumes of water, followed by 3 volumes of lysis buffer 
containing 0.1 mM PMSF using an FPLC (AKTA Purifier UPC10; GE Healthcare) in a cold 
cabinet at 4°C. Filtered supernatant was added to the washed column using a 10 ml super-loop. 
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The column was washed with lysis buffer containing 0.1 mM PMSF until no more protein 
eluted. 
Gradient elution with imidazole (Buffers A and B, Table 2.2) was carried out using 20 column 
volumes of elution buffer containing 0.1 mM PMSF and 0.5 ml fractions collected. Ten 
microlitres of each fraction were removed and added to 10 µl water and 10 µl 3x SDS-PAGE 
loading buffer and analysed by SDS-PAGE. The remaining fractions were stored at -80°C. 
3.2.4 Amicon buffer exchange 
After confirmation by SDS-PAGE and western blot analysis, the pooled eluate was loaded in a 
15 ml Amicon filter tube 30 K (Merck Millipore). The tube was centrifuged at 4000 xg for 30 
min to 1 h at 4°C and centrifugation continued until approximately 250-500 µl of product 
remained in the filter tube.  
The product was then transferred to a 1.5 ml microcentrifuge tube and diluted 1:10 with Buffer 
A for Mono S purification. 
 
3.2.5 Protein purification (Mono S FPLC) 
The FPLC system was prepared in the same way as for His-Trap purification preparation, 
however using buffers used for Mono S purification. The column was loaded at the same flow 
rate and the flow through collected. The column was washed with buffer A and a 20 ml linear 
gradient of KCl (50 mM – 1 M) was performed. Fractions were collected based upon the 280 
nm peak observed upon the real time chromatogram, Fractions were analysed by SDS-PAGE 
and western blot and stored in elution buffer (buffer B). 
3.2.6 SDS-PAGE 
Two 10% SDS-PAGE gels were prepared in Bio-Rad mini-protean apparatus. Ten millilitres 
of separating gel were prepared by combining 3.4 ml 30% acrylamide, 2.7 ml of separating 
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buffer (Table 2.2), 100 µl of 10% (w/v) APS and 10 µl TEMED. The separating gel mixture 
was poured between the plates and overlaid with 100% ethanol and left to set for >30 min. The 
ethanol was washed off and the plates dried using 3MM filter paper. The 5% stacking gel was 
prepared by combining 1.34 ml 30% acrylamide, 2.6 ml stacking gel buffer, 10 µl of 10% (w/v) 
APS and 10 µl TEMED and poured onto the separating gel. A well-forming comb was put in 
place (10 or 15 wells) and the gel left to set for >30 min. 
Samples were re-suspended in 3x SDS-PAGE loading buffer and heated at 95°C for 5 min. The 
gel was unwrapped and the white strip and comb were removed and the wells washed with 
water. The SDS-PAGE apparatus was assembled and 1x TGS added to the reservoir and the 
outer tank filled with ~2 cm of buffer. One microlitre of protein marker, 10 µl un-induced and 
5 µl induced of protein samples were loaded, and electrophoresis carried out at 125V for 2 h. 
One SDS-PAGE gel was stained with InstantBlue (Expedeon) for about 15 min to examine 
overall protein staining, while the other gel was transferred to Immobilon FL membrane (EMD 
Millipore) at 25 V for 1.5 h in WTB. Following transfer, the membrane was analysed by 
immunoblotting using anti-His-tag antibodies. 
 
3.2.7 Western Blotting Protocol 
The Immobilon FL PVDF membrane was prepared by placing it in methanol for 15 s then 
washing in dH2O for 1 min and then placed in transfer buffer for 1 to 2 min. A plate snapper 
was used to remove the gel and then the gel rinsed briefly in transfer buffer. 
The transfer was set up the as following order: sponge, filter paper, gel, membrane, filter paper, 
and sponge and run for 1.5 h at 25 V. 
The membrane was rinsed in PBS for a few minutes then blocked for 1 h in Odyssey blocker 
(diluted 1:1 in PBS). 
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The membrane was then incubated with the primary antibody, a mouse anti-His monoclonal 
antibody (Novagen) at a dilution of 1:1000 overnight at 4°C. The membrane was then washed 
three times in PBS-Tween-20 for 5 min before incubation with a 1:10,000 dilution of Alexa 
Fluor 680 goat anti-mouse secondary antibody (Thermo Fisher) for 1 h at room temperature 
and protected from light. The membrane was washed three times for 5 min in PBS-Tween-20. 
Finally, the membrane was washed in PBS for 5 min to remove excess Tween-20 and scanned 
using an Odyssey imaging system (LI-COR). 
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3.3 Enzyme Activity Methods  
3.3.1 NaBH4-trapping assay  
The trapping assay was carried out using 300 nM of purified proteins and 5 nM oligonucleotide 
substrate in total volume of 10 µL of reaction buffer and 1 µL of 1 M NaBH4 solution added 
prior to incubating the reaction at 30°C for 20 min. The reaction was stopped by the addition of 
10 µL of 3x SDS-PAGE loading buffer and heated to 95°C for 5 min. Samples were loaded 
onto 10% SDS-PAGE gels and electrophoresis carried out at 125V for 2 h, then the gel was 
visualised using an Odyssey imaging system. 
3.3.2 Denaturing Polyacrylamide/Urea Gel Preparation  
The gel was prepared by adding 16.8 g urea into a 50 ml Falcon tube followed by 8 ml of 5x 
TBE and 10 ml of 30% (w/v) polyacrylamide gel solution. The mixture was made up to 40 ml 
with dH2O and mixed thoroughly.  Then, 250 µL of 10% (w/v) APS and 25 µL TEMED were 
added just before pouring the gel mix into the vertical gel cassette and a 10 well comb fitted on 
top. The gel was left for approximately 30 min to set and samples were loaded and 
electrophoresis carried out at 300 V for 90 min. 
3.3.3 DNA Glycosylase/lyase Activity Assays 
The assays were carried out using 300 nM of purified proteins and 5 nM of oligonucleotide 
substrate in a total volume of 10 µL of reaction buffer (Table 2.3). The reaction mixtures were 
incubated at 30°C for 20 min and the substrate and product bands separated by electrophoresis 
through 20% denaturing polyacrylamide/urea gels and visualised using the Odyssey imaging 
system. 
Increasing protein concentrations (150 nM, 300 nM and 600 nM) and incubation times 20 min 
and 30 min) and different temperatures (30°C and 37°C) were used in order to optimise the 
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reaction conditions. The reactions were stopped using 10 µl of loading buffer (Table 2.3). then 
heated for 5 min at 95°C. 
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4 Results 
4.1 Overview 
In order to express hNEIL3-FL and the four truncated versions of hNEIL3 in E. coli, the 
pETDuet-2 expression vector described by Lui et al. (2012) was used. To achieve this, 
pETDuet-2 containing the murine NEIL3 (MmNEIL3) cDNA was used as the starting material. 
Briefly, the ORF6-MmNEIL3 DNA (see Figure 4.14) was removed from the vector using NdeI 
and XhoI restriction enzymes and then replaced with the ORF6 sequence fused to one of the 
hNEIL3 cDNAs that had been obtained by PCR. This was the first stage of the project. 
 
However, direct cloning of the ORF6-hNEIL3 DNAs into pETDuet-2 using restriction digests 
with NdeI and XhoI was not possible, since there is an NdeI restriction site at position 864 in 
the hNEIL3 cDNA (Figure 4.1). In addition, pETDuet-2 lacked any other restriction sites that 
could have been used in place of NdeI. The only exception to this was hNEIL3-843, because 
the NdeI restriction site at position 864 is beyond the end of the hNEIL3-843 sequence. 
Therefore, to overcome this problem and achieve successful cloning of the majority of the 
hNEIL3 cDNAs into pETDuet-2, a multistep cloning strategy had to be designed. 
 
First, the cDNAs of hNEIL3-(843, 1044, 1236, 1506 and full length) were amplified (Figure 
4.5) from the original commercial clone, pCMV6-AC-hNEIL3 and then transferred to the 
pET30b-ORF6 vector, which had previously been prepared in our lab and was obtained from 
lab stocks (Balis, 2013). After successful cloning of the various hNEIL3 cDNA inserts into 
pET30b-ORF6 to generate an ORF6-hNEIL3 overlapping fusion sequence ( 
Figure 4.2), two different strategies were required to prepare the final pETDuet-2 constructs. 
For ORF6-hNEIL3-843, the combined sequence was simply released by NdeI and XhoI double-
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digest (Figure 4.15) and subsequently cloned into the pETDuet-2 expression vector. However, 
for the construction of pETDuet-2-hNEIL3-(1044, 1236, 1506 and full length) clones, a 
modified cloning strategy had to be used, because direct cloning of the hNEIL3 inserts was not 
possible due to the NdeI site in the hNEIL3 cDNA sequence at position 864 (Figure 4.1) Thus, 
with the exception of hNEIL3-843, all other ORF6-hNEIL3 sequences were first PCR amplified 
from pET30b-ORF6-hNEIL3 (Figure 4.12 and Figure 4.13) and the amplicons digested with 
XhoI. The amplicons thus had a blunt 5ʹ-end and a XhoI site at the 3ʹ-end to enable cloning into 
a prepared pETDuet-2 vector (Figure 4.15). For this, pETDuet-2 was first cut with NdeI and 
the product incubated with mung bean endonuclease to create a blunt end. Following DNA 
purification, the treated linear plasmid was incubated with XhoI to create the 3ʹ-end. Thereafter 
the ORF6-hNEIL3 inserts were cloned into pETDuet-2 using standard procedures. 
 
 
 
 
Figure 4.1 Map of the pET30a and pETDuet-2 expression vectors containing human NEIL3. 
Adapted from (Liu et al., 2012)  
 ORF6-hNEIL3 insert restriction map 
Figure 4.1 shows ORF6 at the start of the insert with NdeI site used in the cloning, and an XhoI 
site at end of the insert followed by His-tag i also shows the multi cloning site of pETDuet 
vector accommodating EcoMapy168A, ORF6-hNEIL3   
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Figure 4.2 Sequence of 0RF6-hNEIL3   
Figure 4.2 represents the junctions between NEIL3 cDNA sequences and the ORF6 sequence 
at the 5ʹ end, shows the NdeI site, the ORF6 and the red highlight (AT) shows the overlapping 
nucleotides at the end of ORF6 sequence and the start of hNEIL3.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3 Illustrations of the hNEIL3 inserts after cloning into pETDuet-2. 
Vector map of pETDuet-2-hNEIL3 shows EcoMapY168A, the leading ORF6 sequence 
followed by hNEIL3 and the His tag downstream the C-terminal of hNEIL3.  
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Using this method, four out of the five hNEIL3 cDNAs were successfully cloned into 
pETDuet-2 vector indicating the positions of EcoMap, ORF6 and hNEIL3-(843, 1044, 1506 
and full length) (Figure 4.3)., Cloning of pETDuet-2-hNEIL3-1236 was not successful and it 
was decided to work with the other four clones only. The successful clones were checked by 
restriction enzyme digests and confirmed by DNA sequencing. Of these, three out of the four 
constructs [hNEIL3-(843, 1044, and full length)] were successfully expressed in E. coli and 
the proteins purified by FPLC using His-Trap column for [hNEIL3-(843 and 1044)], utilizing 
the 6 histidine codon sequence (His-tag) following the C-terminal of hNEIL3 inserts in the 
pETDuet-2 expression vector, and His-Trap followed by Mono S columns for hNEIL3-FL 
(Figure 4.17-Figure 4.27). Expression and purification of the recombinant proteins was 
analysed by SDS-PAGE and western blotting and the purified proteins tested for activity 
using enzyme activity assays (Figure 4.28-Figure 4.50). The recombinant hNEIL3 proteins 
proved to be active on a variety of oxidised DNA bases in different contexts, including single-
stranded DNA and at different positions in a model DNA replication fork. 
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4.2 Cloning  
4.2.1 Cloning of hNEIL3 cDNA inserts into the pET30b-ORF6 vector 
The pCMV6-AC-hNEIL3 plasmid DNA was first checked for the presence of hNEIL3 by 
restriction digestion with EcoRI and XhoI, before being subjected to PCR to amplify the target 
hNEIL3 cDNAs. The two enzymes cut in the multiple cloning sites (MCS) either side of the 
hNEIL3 cDNA insert in the vector.  
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4 Restriction digests of pCMV6-AC-hNEIL3 with EcoRI and XhoI. 
Lane 1, Hyperladder I; lane 2, uncut plasmid; lane 3, double-digest (EcoRI and XhoI); lane 4, 
uncut plasmid; lane 5, single digest with XhoI; lane 6, single digest with EcoRI. 
 
In Figure 4.4, the single digest with either EcoRI or XhoI shows one band of about 5000 bp 
confirming that both enzymes cut the plasmid once and linearize it, while a double-digest 
reveals two bands, one around 2000 bp in length (hNEIL3 cDNA is 1818 bp) confirming the 
presence of hNEIL3 cDNA. The additional base pairs (approximately 182 bp) are due to the 
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positions where the two enzymes cut the vector in the MCS and the distance to the hNEIL3 
sequence. 
 
4.2.2. Amplification of hNEIL3 cDNAs 
After confirming the presence of the hNEIL3 in pCMV6-AC, PCR reactions were carried out 
using the plasmid DNA as template to amplify the different hNEIL3 cDNAs. While a common 
forward primer (lacking the first AT nucleotides of the hNEIL3 ATG) was used for all PCR 
reactions, reverse primers containing a XhoI restriction site were designed according to the 
length of each hNEIL3 insert (Table 3.1). 
 
 
 
 
 
 
 
 
 
Figure 4.5 Amplification of full-length and truncated hNEIL3 cDNAs from pCMV6-AC-
hNEIL3. 
Lane 1, Hyperladder I; lane 2, hNEIL3-843; lane 3, hNEIL3-1044; lane 4, hNEIL3-1506; lane 
5, hNEIL3-1236; lane 6, hNEIL3-full-length.  
 
The bands observed in Figure 4.5 indicate that all the PCR reactions were successful and gave 
rise to bands of the expected size. However, the full-length hNEIL3 cDNA is relatively faint 
compared to the other amplicons. Following purification, the PCR products were then ligated 
into the pET30b-ORF6 vector. 
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4.2.3. Preparation of hNEIL3 cDNAs and pET30b-ORF6 vector for ligation. 
The hNEIL3 cDNAs amplified in the previous step were prepared for ligation to the ORF6 
sequence in the previously constructed pET30b-ORF6 vector to create ORF6-hNEIL3 inserts 
that will then be cloned into the pETDuet-2 expression vector. To begin, pET30b-ORF6 was 
digested with EcoRV and XhoI restriction enzymes to yield compatible ends with the hNEIL3 
cDNA inserts. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6 Restriction digests of pET30b-ORF6 with XhoI and EcoRV.  
Lane 1, Hyperladder I; lane 2, uncut plasmid; lane 3, XhoI; lane 4, XhoI and EcoRV; lane 5, 
EcoRV; lane 7, uncut plasmid; lane 8, XhoI; lane 9, XhoI and EcoRV; lane 10, EcoRV; lane 
12, uncut plasmid; lane 13, XhoI; lane 14, XhoI and EcoRV; lane 15, EcoRV. 
 
 
As shown in Figure 4.6, pET30b-ORF6 was subject to single- and double-digests with XhoI 
and EcoRV. The vector was linearized creating a XhoI site overhang at the 3ʹ end and a blunt 
end at the 5ʹ end resulting from digestion with EcoRV. These sites are compatible with the 5ʹ 
blunt end in the hNEIL3 PCR products and a 3ʹ XhoI site overhang resulting from digestion of 
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the inserts with XhoI. The result shows the expected band size of linearized vector between 
5000 and 6000 bp in lanes 3, 4, 5, 8, 9, 10, 13, 14, 15 (vector size 5421 bp). 
 
Reverse primers for all hNEIL3 inserts were designed with a XhoI site to create an overhang 
compatible with the XhoI site of the ORF6 sequence in the vector (Table 3.1). All hNEIL3 PCR 
products were subject to restriction digestion with XhoI, however, the agarose gel picture is not 
shown as this digest will only reduce the length of the DNA by a few base pairs and therefore 
the difference cannot be visualized in an agarose gel. 
 
Following preparation of the hNEIL3 inserts and the pET30b-ORF6 vector, the inserts were 
ligated with the vector using T4 DNA ligase at a 3:1 insert/vector ratio. The ligation mixtures 
were transformed into E. coli NovaBlue competent cells using the transformation method 
described in Section 3.1.63.1.9. 
 
4.2.4. Testing E. coli colonies for successful ligation and transformation of hNEIL3 inserts 
into pET30b-ORF6 
Following overnight growth of the transformed E. coli cells on LB-agar plates, a number of 
colonies were picked and grown in 5 ml LB (30 mg/ml kanamycin) culture overnight at 37°C. 
The DNA was extracted as described in Section 3.1.2 and the plasmid DNA was subjected to 
restriction digestion with NdeI to confirm the successful ligation of the inserts into the pET30b-
ORF6 vector. NdeI cuts the pET30b-ORF6-hNEIL3 vector at the start of the ORF6 sequence 
and at position 864 bp in the hNEIL3 cDNA, thus in the presence of hNEIL3 inserts (except for 
hNEIL3-843), NdeI cuts both the vector and hNEIL3 cDNA resulting in a band of 
approximately 909 bp (864 bp of hNEIL3 + 45 of ORF6) (Figure 4.7). This reaction was used 
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as a confirmatory test for the ligation of the hNEIL3 cDNAs into pET30b-ORF6 except of 
course, for hNEIL3-843.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7 Restriction digests of pET30b-ORF6-hNEIL3 (1236, 843, and 1044) with NdeI.  
Lane 1, Hyperladder I; lanes 2 - 5, hNEIL3-1236; lane 7, Hyperladder I; lanes 8 – 11, hNEIL3-
843; lanes 13 - 16 hNEIL3-1044. 
 
In Figure 4.7, lanes 2 and 3 contain plasmids with the hNEIL3-1236 insert as shown by the 
presence of the linearized vector between 5000 bp and 6000 bp (5421 bp) and a second band 
between 800 bp and 1000 bp. As NdeI cuts the hNEIL3 cDNA at 909 bp, this confirms the 
presence of hNEIL3-1236 in the vector. Conversely, lanes 4 and 5 show only one band at the 
size of linearized vector indicating the absence of the hNEIL3-1236 insert in the vector 
(negative colonies). Figure 4.7 also shows that in lanes 15 and 16 positive clones of hNEIL3-
1044 were obtained, while those in lanes 13 and 14 lacked the hNEIL3 insert. 
 
For pET30b-ORF6-hNEIL3-843, only one band, representing the linearized vector can be seen 
in lanes 8 and 9 in Figure 4.7, as NdeI cuts only at the start of the ORF6 sequence and not in 
the hNEIL3-843 insert. The double bands observed in lanes 10 and 11 in Figure 4.7 most likely 
represent incomplete digestion of the plasmid, something also observed in lanes 13 – 16. 
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Confirmation that the clones in lanes 8 – 11 contained hNEIL3-843 using a separate restriction 
enzyme digest is shown in Figure 4.8. Here, hNEIL3-843 was subject to a double-digest with 
NdeI and XhoI to release the ORF-hNEIL3-843 insert from the vector confirming the presence 
of the insert in both clones tested as shown in Figure 4.8 (lanes 3 and 5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.8 Restriction digests of pET30b-ORF6-hNEIL3-843 with NdeI and XhoI.  
Lane 1, Hyperladder I; lanes 2 and 4, uncut plasmid; lanes 3 and 5, double-digest with XhoI 
and NdeI. 
 
In Figure 4.8, the ORF6-hNEIL3-843 insert was released from both clones tested (lanes 3 and 
5), and bands of the predicted size, between 800 bp and 1000 bp obtained (843 bp hNEIL3+47 
ORF6), as NdeI cuts at the start of ORF6 and XhoI cuts the end of hNEIL3-843. The bands 
were cut from the agarose gel and purified as described in Section 3.1.83.1.8 for cloning into 
pETDuet-2. 
 
Similarly, pET30b-ORF6-hNEIL3 (1506 and full length) was subjected to an NdeI restriction 
digest to confirm the presence of inserts in the picked clones.  
68 
 
 
 
 
 
 
 
 
         
 
 
 
Figure 4.9 Restriction digests of pET30b-ORF6-hNEIL3 cDNAs (1506, full length) with NdeI: (C 
for Control, D for digest).  
Lane 1, Hyperladder I; lane 3, hNEIL3-FL clone 1 NdeI digest; lane 4, hNEIL3-FL clone 1 
uncut; lane 6, hNEIL3-FL clone 2 uncut; lanes 5 and 7, hNEIL3-FL clone 2 NdeI digest; lane 
9, hNEIL3-1506 clone 1 uncut; lane 10, hNEIL3-1506 clone 1 NdeI digest; lane 11, hNEIL3-
1506 clone 2 uncut; lane 12, hNEIL3-1506 clone 2 NdeI digest; lane 13, hNEIL3-1506 clone 3 
uncut; lane 14, hNEIL3-1506 clone 3 NdeI digest. 
 
The results shown in Figure 4.9 indicate that hNEIL3-1506 was successfully ligated into the 
pET30b-ORF6 vector. Following restriction enzyme digestion with NdeI, the three clones of 
hNEIL3-1506 show an upper band at the size of the linearized vector and a lower band at 
position of the hNEIL3 cut by NdeI (909 bp), confirming the successful cloning of hNEIL3-
1506 into the pET30b-ORF6 vector. The loss of the top band in lane 10 and 12 is due to efficient 
plasmid digestion in comparison to controls in lanes 9, 11 and 13 where the plasmid DNA 
samples were not fully digested by NdeI restriction enzyme. 
 
For the full length hNEIL3 the two clones were negative for the presence of the insert as no 
band shows at the predicted position of the hNEIL3 cut by NdeI (Figure 4.9), indicating that 
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the ligation and transformation of full-length hNEIL3 into pET30b-ORF6 vector had not been 
successful. Therefore, the ligation and transformation experiment was repeated for pET30b-
ORF6-hNEIL3-FL and the restriction digest analysis repeated. The result of the NdeI digest, 
shown in Figure 4.9, confirmed the successful ligation of hNEIL3-full length into pET30b-
ORF6. 
 
 
 
 
 
 
 
 
 
Figure 4.10 Restriction digests of pET30b-ORF6-hNEIL3-FL with NdeI. 
Lane 1, Hyperladder I; lanes 2, 3, 5, 6, 8, 9, 11 and 12, NdeI digests. 
Lanes 2, 3, 5, 9 and 11 show only one band of the linearized vector indicating that the insert 
was not successfully ligated with the vector. However, lanes 6, 8 and 12 show a linearized 
vector band size between 5000 bp and 6000 bp (5421 bp) and a lower band between 800 bp and 
1000 bp where NdeI cuts hNEIL3 confirming the successful ligation of the insert with vector.  
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4.2.5. Cloning of ORF6-hNEIL3 inserts into pETDuet-2.  
4.2.6. Cloning of ORF6-hNEIL3-843 inserts into the pETDuet-2 expression vector. 
In order to prepare pETDuet-2 for ligation with ORF6-hNEIL3-843, it was subjected to 
restriction digestion with NdeI and XhoI. This created compatible ends for the ORF6-hNEIL3-
843 insert to allow ligation into pETDuet-2. Ligation of the insert and vector and transformation 
of E. coli competent cells was carried out as described in Sections 3.1.6 and 3.1.9. 
 
After transformation of E. coli, six colonies were picked and tested for the presence of the 
hNEIL3-843 insert. DNA extracted from the colonies was subject to double-digestion with 
NdeI and XhoI to confirm the successful cloning of hNEIL3-843 into pETDuet-2.  
 
 
 
 
 
 
 
 
 
Figure 4.11 Double digest of pETDuet-2-ORF6-hNEIL3-843 with NdeI and XhoI.  
Lane 1, Hyperladder I; lane 2, uncut plasmid; lanes 4, 6, 8, 10, 12 and 14, hNEIL3-843, no 
samples were loaded in lanes 5, 7,9,11 and 13. 
 
In Figure 4.11, only the clone in lane 8 did not contain the cDNA insert, while the clones in 
lanes 4, 6, 10 and 12 were positive showing an upper band equivalent to the size of the linearized 
plasmid and lower band at the expected size of hNEIL3-843. 
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4.1.7. Cloning of ORF6-hNEIL3-(1044, 1236, 1506 and full length) inserts into the 
pETDuet-2 expression vector. 
For the ORF6-hNEIL3-(1044, 1236, 1506 and FL) inserts, a different cloning strategy was 
designed. This consisted of amplifying each of the hNEIL3 cDNAs from pET30b-ORF6-
hNEIL3 (Figure 4.12 andFigure 4.13) and then digesting the PCR product with XhoI to create 
a XhoI 3ʹ-end overhang and a blunt end at the 5ʹ-end of the cDNA to be compatible with the 
XhoI and blunt ends of pETDuet-2. 
pETDuet-2 was first prepared using NdeI to linearize the vector and then blunting the 5ʹ-end 
NdeI overhang with mung bean nuclease. Following clean-up, the linearized vector was then 
cut with XhoI. This resulted in linearized plasmid DNA with a blunt end at the 5ʹ-end and a 
XhoI overhang at the 3ʹ-end, Thereafter, ligation of the cDNA inserts to linearized pETDuet-2 
was carried out to prepare pETDuet-2-ORF6-hNEIL3-(1044, 1236, 1506 and FL) constructs 
before transformation into E. coli competent cells. 
 
 
 
 
 
 
 
Figure 4.12 Amplification of ORF6-hNEIL3 cDNAs 1044 and 1236.  
Lane 1, Hyperladder I; lanes 2, 4 and 6, control samples (no primers were added); lanes 3 and 
5, ORF6-hNEIL3-1044; lane 7, ORF6-hNEIL3-1236. 
 
Figure 4.12 shows that the ORF6-hNEIL3-1044 and ORF6-hNEIL3-1236 inserts were 
successfully amplified from pET30b-ORF6-hNEIL3, with bands of approximately the expected 
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size being obtained. However, the PCR product for ORF6-hNEIL3-1236 was much fainter than 
for the 1044 equivalent. 
 
In order to construct the pETDuet-2-ORF6-hNEIL3-FL expression vector, PCR of ORF6-
NEIL3-FL was carried out using different annealing temperatures (74ºC and 76ºC) in order to 
determine the optimal PCR conditions (Figure 4.13).  
 
 
 
 
 
 
 
 
 
 
Figure 4.13Amplification of ORF6-hNEIL3-FL by PCR at two annealing temperatures.  
Lane 1, Hyperladder; lanes 2 and 4, control samples (no primers added); lane 3, annealing 
temperature 76°C; lane 5, annealing temperature 74°C. 
 
 
In Figure 4.13 it can be seen that ORF6-hNEIL3-FL was successfully amplified from the 
pET30b-ORF6-hNEIL3-FL plasmid DNA in both samples, although using an annealing 
temperature of 74°C resulted in more PCR product and this temperature was used for the 
subsequent experiments. 
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The ORF6-hNEIL3 PCR products (inserts) were subject to restriction digestion with XhoI to 
create compatible ends with pETDuet-2 as previously described. Then the inserts were purified 
using the PCR clean up method described Section 3.1.8 to be cloned into pETDuet-2. 
 
4.1.8. Cloning ORF6-hNEIL3 inserts into pETDuet-2. 
The original pETDuet-2-ORF6-MmNEIL3 vector was subjected to a double-digest with NdeI 
and XhoI to release the ORF6-MmNEIL3 DNA sequence from the expression vector and 
confirm that the correct plasmid had been obtained.  
 
 
 
 
 
 
 
 
 
 
Figure 4.14 Double-digest of pETDuet-2-ORF6-MmNEIL3 with NdeI and XhoI. 
Lane 1, Hyperladder I; lanes 2 - 5, pETDuet-2-ORF6-MmNEIL3 double-digest with NdeI and 
XhoI.  
 
 
In Figure 4.14, ORF6-MmNEIL3 was released from all four clones of pETDuet-2-ORF6-
MmNEIL3 revealing an upper band corresponding to the size of the vector and a lower band at 
the size of ORF6 and the NEIL3 coding sequence from M. musculus (1821 bp). Thus the ORF6-
MmNEIL3 DNA was released from pETDuet-2 in all four clones. 
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In order to prepare pETDuet-2 for ligation with the ORF6-hNEIL3 sequences, the vector was 
first digested with NdeI. The restriction enzyme reaction mixture was incubated at 37°C for 90 
min, and then the NdeI enzyme was inactivated by placing the reaction tube at 65°C for 20 min. 
The reaction mix was then incubated with mung bean nuclease to blunt the NdeI overhang and 
the DNA was purified using a PCR-Clean Up kit (Section 3.1.7 and 3.1.8  ).  
 
After purification, pETDuet-2 was digested with XhoI and all of the reaction mix was loaded 
onto a 0.8% agarose gel and subjected to electrophoresis to separate the ORF6-MmNEIL3 DNA 
from the pETDuet-2 vector (Figure 4.15). The bands were visualized on a UV-transilluminator 
and the upper band corresponding to the pETDuet-2 plasmid cut from the gel, purified and 
subsequently used for ligation with hNEIL3 inserts. 
 
 
 
 
 
 
 
 
Figure 4.15 pETDuet-2-ORF6-MmNEIL3 cut with (NdeI + Mung Bean Nuclease + XhoI) 
Lane 1, Hyperladder I; lanes 3 and 4, pETDuet-2-ORF6-MmNEIL3 cut with (NdeI + mung 
bean nuclease + XhoI). 
 
In lanes 3 and 4 of Figure 4.15, an upper band corresponding to pETDuet-2 and a lower band 
at the size of the ORF6-MmNEIL3 are evident, confirming the release of ORF6-MmNEIL3 
from the plasmid. 
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T4 DNA ligase protocol was used as described in Section 3.1.6 to achieve a 3:1 insert/vector 
ratio to ligate the ORF6-hNEIL3 inserts into the pETDuet-2 expression vector. The ligation 
mixtures were transformed into E. coli NovaBlue competent cells using the transformation 
method described in Section 3.1.9, Colonies were picked for overnight cultures then tested for 
the presence of the inserts in the expression vector by restriction enzyme digest with NdeI 
(because NdeI cuts the ORF6-hNEIL3 insert at position of 909 bp (Figure 4.16 A, B and C) 
revealing a band at 909 bp on the agarose gel). 
 
 
 
 
 
 
 
 
 
Figure 4.16 Restriction Digests of A. pETDuet-2-ORF6-hNEIL3-1044, B. pETDuet-2-ORF6-
hNEIL3-1506 and C. pETDuet-2-ORF6-hNEIL3-FL with NdeI. 
A. Lane1, Hyperladder I; lane 2, uncut plasmid cDNA; lanes 3 - 8, pETDuet-2-ORF6-hNEIL3-
1044 with NdeI. B. Lane1, Hyperladder I; lane 2, uncut plasmid; lanes 3 - 6 pETDuet-2-ORF6-
hNEIL3-1506 clones. C. Lane 1, Hyperladder I; lane 2, uncut plasmid cDNA; lanes 3 - 8 
pETDuet-2-ORF6-hNEIL3-FL digested with NdeI.  
 
Figure 4.16 A shows positive clones in lanes 3 - 5 indicated by the presence of a band around 
900 bp where NdeI cuts the ORF6-hNEIL3 insert, while the clones in lanes 6 - 8 were negative. 
Figure 4.16 B shows that the clones in lanes 3 and 4 are positive for the presence of the insert 
with an upper band corresponding to the linearized vector and a lower band between 800 bp 
and 1000 bp indicating digestion of hNEIL3 by NdeI, while the clones in lanes 5 and 6 do not 
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show any insert present.Error! Reference source not found. Figure 4.16 C shows that clones 
in lanes 7 and 8 were positive for the insert DNA, indicated by the presence of a band about 
900 bp, while the clones in lanes 3 - 6 did not contain the correct insert. 
Following these experiments, lab stock were made of all the positive clones of the pETDuet-2-
ORF6-hNEIL3 cDNAs (843, 1044, 1506 and FL) and stored in -80ºC for future use. 
Unfortunately, despite several attempts, the ORF-hNEIL3-1236 could not be cloned into 
pETDuet-2. The reasons for this are not clear. 
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4.1.9. DNA Sequencing of the ORF6-hNEIL3 inserts in pETDuet-2. 
Plasmid DNA of the pETDuet-2-ORF6-hNEIL3-(843, 1044, 1506 and FL) clones were sent to 
Eurofins for sequencing using forward and reverse primers for each clone. The results obtained 
confirmed the successful cloning of all constructs, (Sequences data presented in Appendix). 
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4.3 Protein Expression 
4.3.1 Protein expression test results 
Protein expression was first tested for each hNEIL3 truncation by growing 30 ml cultures under 
different conditions and proceeding with 1 ml aliquots for analysis by SDS-PAGE and western 
blotting. As the results show (Figure 4.17, Figure 4.19, Figure 4.21 andFigure 4.23) all hNEIL3 
protein expression tests were successful and also confirmed the co-expression of the EcoMap 
gene (32 kDa), while western blotting with an His-Tag antibody confirmed the expression of 
hNEIL3 his-tagged proteins revealing bands at the predicted protein sizes of: hNEIL3-(843) 
31.2 kDa, hNEIL3-(1044) 38.6 kDa, hNEIL3-(1506) 55.7 kDa and hNEIL3-full length 67.3 
kDa. 
 
To determine the optimum conditions for protein over-expression, the small bacterial cultures 
were induced with IPTG and incubated at different temperatures for increasing lengths of time. 
Figure 4.17 shows the SDS-PAGE and western blot analyses of such an experiment with 
pETDuet-2-hNEIL3-843, where bacterial cultures were induced and incubated at either 16°C 
or 37°C for 3 h and 18 h. At 37°C no appreciable difference in expression was observed 
following incubation for 3 h or 18 h (Figure 4.17B, lanes 3 - 4), however, at 16°C, significant 
recombinant protein expression was only observed after incubation for 18 h (Figure 4.17B, 
lanes 6 - 7). 
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Figure 4.17 SDS-PAGE and western blot analyses of pETDuet-2-hNEIL3-843 test protein 
expression.  
(A) SDS-PAGE gel, and (B) western blot of hNEIL3-843. Lane 1, protein size marker; lane 2, 
hNEIL3-843 uninduced; lane 3, hNEIL3-843 induced for 3 h at 37°C; lane 4, hNEIL3-843 
induced for 18 h at 37°C; lane 5, hNEIL3-843 uninduced; lane 6, hNEIL3-843 induced for 3 h 
at 16°C; lane 7, hNEIL3-843 induced for 18 h at 16°C. 
 
In summary, analysis of Figure 4.17A shows that a band of approximately size of hNEIL3-843 
(31.2 kDa) is present in most of the induced samples (lanes 3, 4 and 7). However, as the 
molecular weight of the co-expressed EcoMap is 32 kDa, it is not possible to tell by SDS-PAGE 
alone, if one or both proteins have been expressed. However, in Figure 4.17B, the western blot 
clearly identifies the His-tagged NEIL3-843 with His-tag antibodies, thus confirming the 
expression of hNEIL3-843 in E. coli cells. The expression of both proteins is more clearly 
observed in later Figures (e.g.Figure 4.19), where the molecular weight of the co-expressed 
proteins is significantly different. 
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Following these test results, a 400 ml culture was induced with 1 mM IPTG and incubated at 
16°C for 18 h and the protein extracted and subjected to His-Trap column purification. The 
results are given in Figure 4.18, which shows both the SDS-PAGE and western blotting of 
protein fractions following His-Trap purification of hNEIL3-843. 
 
 
 
 
 
 
 
 
 
 
Figure 4.18 SDS-PAGE (A) and western blotting (B), of column fractions following His-Trap 
FPLC purification of hNEIL3-843.  
(A) SDS-PAGE of column fractions, lane 1, protein size marker; lane 2, whole cell extract 
(WCE), lanes 3 – 13, column fractions 11 - 25; lane 14, flow-through (FT). (B) Western blot of 
column fractions. Lane 1, protein size marker; lane 2, whole cell extract; lane 3, flow-through; 
lanes 4 – 14, column fractions 5 - 25. 
 
Figure 4.18 confirms the successful expression and purification of hNEIL3-843 protein. Most 
of the E. coli proteins and EcoMap were eluted between fractions 7 and 9 while the target 
protein, hNEIL3-843) was eluted between fractions 17 and 23. Bands of the size of the target 
protein can be clearly seen after SDS-PAGE in Figure 4.18A and were confirmed to be the His-
tagged hNEIL3-843 by western blotting as shown in Figure 4.18B. also show smaller size 
bands, suggested being degradation product of the recombinant protein. 
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Following the successful expression and purification of hNEIL3-843, similar experiments were 
undertaken with hNEIL3-1044 and the results of the test expression are given in Figure 4.19 
The results are similar to those obtained for hNEIL3-843 and again an incubation temperature 
of 16°C and incubation period of 18 h was chosen. 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.19 SDS-PAGE (A) and western blot (B) analyses of pETDuet2-hNEIL3-1044 test 
protein expression. 
Lane 1, protein size marker; lane 2, hNEIL3-1044 uninduced; lane 3, hNEIL3-1044 induced 
for 3 h at 37°C; lane 4, NEIL3-1044 induced for 18 h at 37°C; lane 5, hNEIL3-1044 uninduced; 
lane 6, hNEIL3-1044 induced for 3 h at 16°C; lane 7, hNEIL3-1044 induced for 18 h at 16°C. 
 
Following SDS-PAGE, Figure 4.19A shows two strong staining polypeptide bands in the 
induced samples; the first around 37 kDa, equivalent to the size of hNEIL3-1044, and the 
second approximately 32 kDa, equivalent to the size of EcoMap. The western blot with a His-
Tag antibody in Figure 4.19B confirms the identity of the larger band as hNEIL3-1044, 
although other smaller bands are observed, especially in the samples incubated at 37°C. These 
bands are much reduced when expression was carried out at 16°C (lanes 6 – 7) and are not 
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visible in the equivalent western blot for hNEIL3-843 (Figure 4.17B). They are also not present 
following purification of hNEIL3-1044 (Figure 4.20). Therefore, it may be concluded that 
protein degradation had occurred in these particular samples and that this is not a general 
problem encountered with expression of this recombinant hNEIL3 truncated version. 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.20 SDS-PAGE (A) and western blot (B) of column fractions following His-Trap FPLC 
purification of hNEIL3-1044.  
(A) SDS-PAGE gel, (B) western blot of purified hNEIL3-1044 protein. Lane 1, protein size 
marker; lane 2, hNEIL3-1044 whole cell extract; lane 3, flow through; lanes 4 - 14, hNEIL3-
1044 fractions 5 - 25. 
 
SDS-PAGE and western blotting of the His-Trap protein purification of hNEIL3-1044 are 
shown in Figure 4.20A and Figure 4.20B. Both confirm the expression and purification of the 
target hNEIL3-1044 protein, with most of the recombinant protein eluting in fractions 15 - 21. 
Similar to Figure 4.18 show smaller size bands, suggested being degradation products of the 
recombinant protein. 
 
Following on from the previous experiments, Figure 4.21 shows the SDS-PAGE and western 
blot of pETDuet-2-hNEIL3-1506 test protein expression. Although there is no clear abundant 
band at the predicted size of hNEIL3-1506 after SDS-PAGE at either incubation temperature 
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(Figure 4.21A), the western blot of the same samples shows clear bands at the predicted size of 
55 kDa for hNEIL3-1506, indicating a low level of recombinant protein expression. However, 
good induction of EcoMap expression is observed in the samples incubated at both 37°C (lanes 
3 and 4), and after 18 h at 16°C (lane 7), indicating that recombinant protein expression was 
achieved as expected. The lower level of expression, compared with the smaller hNEIL3 
proteins, is also indicated by the relatively faint bands obtained by western blotting when 
compared with the results of the hNEIL3-(843 and 1044) expression. The western blot also 
indicates the presence of an extra low molecular weight band that is smaller than the hNEIL3-
1506 protein. As this band is observed both in the test expression and after protein purification 
(Error! Reference source not found.), it must be concluded that this represents a protein 
degradation product that contains the C-terminus plus His-Tag part of the recombinant protein. 
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Figure 4.21 SDS-PAGE (A) and western blot (B) analyses of pETDuet-2-hNEIL3-1506 test 
protein expression.  
(A) SDS-PAGE and (B) western blot. Lane 1, protein size marker; lane 2, hNEIL3-1506 
uninduced; lane 3, hEIL3-1506 induced for 3 h at 37°C; lane 4, hNEIL3-1506 induced for 18 h 
at 37°C; lane 5, hNEIL3-1506 uninduced; lane 6, hNEIL3-1506 induced for 3 h at 16°C; lane 
7, hNEIL3-1506 induced for 18 h at 16°C. 
 
Figure 4.22 SDS-PAGE (A) and western blot (B) of column fractions following His-Trap FPLC 
purification of hNEIL3-1506.  
Lane 1, protein size marker; lane 2, hNEIL3-1506 whole cell extract; lane 3, flow through; lanes 
4 - 15 hNEIL3-1506 fractions 5 - 16. 
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Analysis of the SDS-PAGE in Figure 4.22A shows no specific band at the size of the target 
protein (55 kDa) while in Figure 4.22B, the western blot of the purified protein fractions, bands 
at the size of the target protein can be observed in fractions 12 – 16. Smaller bands are also 
visible in Figure 4.22B, which most likely indicate a degradation product of the target protein 
(hNEIL3-1506). The bands at the predicted protein size are relatively faint due to the low 
expression levels and therefore, the amount of the purified protein obtained. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.23 SDS-PAGE (A) and western blot (B) analyses of pETDuet-2-hNEIL3-FL test protein 
expression. 
SDS-PAGE (A) and western blot (B). Lane 1, protein size marker; lane 2 hNEIL3-FL un-
induced; lane 3, hNEIL3-FL induced for 3 h at 37°C; lane 4, hNEIL3-FL induced for 18 h at 
37°C; lane 5, hNEIL3-FL un-induced; lane 6, hNEIL3-FL induced for 3 h at 16°C; lane 7, 
hNEIL3-FL induced for 18 h at 16°C. 
 
Figure 4.23A again shows no specific bands at the size of the hNEIL3-FL protein in induced 
samples but again shows high expression of EcoMap (lanes 3, 4 and 7). In Figure 4.23B, the 
western blot of the hNEIL3-FLwith His-tag antibodies shows two bands in the induced samples, 
one the approximate size of the target protein (67.3 kDa) and one at about 50 kDa. As both of 
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these proteins are detected by the anti:His-tag antibody, it can be assumed that the 50 kDa band 
represents a proteolytic degradation product of hNEIL3-FL that contains the C-terminal 
domains, but lacks the N-terminal DNA glycosylase active site. 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.24 SDS-PAGE (A) and western blot (B) of fractions following His-Trap FPLC 
purification of hNEIL3-FL.  
Lane 1, protein size marker; lane 2, hNEIL3-FL whole cell extract; lane 3, flow through; lanes 
4 – 15, hNEIL3-FL fractions 5 - 16. 
  
 
Error! Reference source not found. and Figure 4.24 show the result of hNEIL3-FL test 
expression and His-Trap purification. Similar to the results observed for hNEIL3-1506, the 
absence of a significant band at the size of the target protein in SDS-PAGE is due to the low 
amount of hNEIL3-FL protein obtained after induction, while the western blot pictures show 
bands at the size of the target protein confirming the expression and purification of hNEIL3-
FL. The western blot also shows that the suspected C-terminal degradation product co-elutes 
with hNEIL3-FL and thus is not separated by the His-Trap purification method, further 
confirming its identity, at least as a His-tagged protein. 
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4.3.2 Protein purification of hNEIL3-FL for activity assays 
While 400 ml cultures were enough to yield useable quantities of hNEIL3-843 and hNEIL3-
1044, to obtain sufficient amounts of the hNEIL3-FL protein, a much larger culture of 
pETDuet-2-ORF6-hNEIL3-FL (1.2 L) was induced with 1 mM IPTG and incubated for 18 h 
at 16°C. The bacterial cells were lysed and the soluble supernatant prepared as described in 
Section 3.2.2. Following His-Trap purification, the fractions were analysed by SDS-PAGE 
and western blotting and the results are shown in Figure 4.25A and B. This shows bands of 
the expected size for hNEIL3-FL and the 50 kDa putative degradation product of the hNEIL3-
FL protein co-eluting principally in fractions 11 – 23. 
 
 
 
 
 
 
 
 
Figure 4.25 SDS-PAGE (A) and western blot (B) of fractions following His-Trap FPLC 
purification of hNEIL3-FL.  
Lane 1, protein size marker; lanes 2 – 11, hNEIL3-FL fractions 5 - 23. 
 
The partially purified protein was then subjected to Mono-S ion exchange chromatography for 
further purification and to reduce any bacterial protein contamination. The resulting fractions 
analysed by SDS-PAGE and western blotting using an anti-His antibody (Figure 4.26A and B). 
Figure 4.26A and B show clear bands at the expected size of hNEIL3, while the bands at the 
size of the degradation protein products appeared to be weaker in comparison with hNEIL3, 
indicating a preferential purification of intact hNEIL3-FL. 
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Figure 4.26  SDS-PAGE (A) and western blot (B) of fractions following Mono S FPLC 
purification of hNEIL3-FL.  
A and B: Lane 1, protein size marker; lane 2, flow through; lanes 2 to 15, fractions 7 - 19. 
 
The western blot membrane in Figure 4.26B was stored at -20°C and later incubated with an 
anti-NEIL3 antibody. The result, given in Figure 4.27, confirmed that the bands observed using 
the anti:His tag antibody were due to hNEIL3 protein. However, the western blot does not show 
any preferential purification of the degradation product from hNEIL3-FL and instead shows a 
very consistent pattern across all the fractions. This must be due to the specificity of the 
polyclonal antibody (Section 3.2.7) to the hNEIL3 polypeptide. 
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Figure 4.27  Western blot (using anti:NEIL3 antibody) of fractions following Mono S FPLC 
purification of hNEIL3-FL. 
A and B: one membrane scanned with two different contrast/channels. Lane 1, protein size 
marker; lane 2 flow through; lanes 2 - 15, hNEIL3-FL fractions 7 - 19. 
 
Fractions containing hNEIL3-FL were pooled and concentrated using an Amicon centrifugation 
filter with a 30,000 MW cut off (Section 3.2.4). These were then used for DNA glycosylase 
activity assays. 
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4.4 DNA Glycosylase Activity Assays 
4.4.1 hNEIL3 purity and stability determination 
The DNA glycosylase activity of the purified recombinant hNEIL3 proteins was tested by 
incubating the proteins with a variety of 5ʹ-fluorescently tagged oligonucleotide substrates 
containing different site-specific oxidised bases for 20 min at 30ºC. The reaction mixtures were 
then loaded onto 10% denaturing polyacrylamide/urea gels for electrophoresis and visualised 
with a fluorescent scanner. The DNA glycosylase activity of the hNEIL3 proteins were tested 
single- and double-stranded oligonucleotides containing a single oxidised base (5- 
hydroxyuracil (5-OHU), thymine glycol (TG) or 7,8-dihydro-8-oxoguanine (8-oxoG)). These 
oxidised bases were also placed at one of three different positions in a model DNA replication 
fork and the activity of the different hNEIL3 proteins analysed. 
To confirm that the observed activity was from the recombinant hNEIL3 proteins and not 
contaminating bacterial DNA glycosylases that had co-purified, a sodium borohydride trapping 
experiment was undertaken. This technique forms a covalent linkage between the DNA 
glycosylase and the fluorescently labelled substrate that can be separated by SDS-PAGE. This 
achieved by the generation of a Schiff base intermediate product, generated through the 
associated AP- lyase of a bifunctional DNA glycosylase, which is reduced by NaBH4 to form 
a covalently bound DNA-protein complex. Thus, the molecular weight of the active proteins 
can be determined. Figure 4.28 shows the result of one such experiment where hNEIL3-843 
and hNEIL3-FL were incubated with a single-stranded oligonucleotide containing 5-OHU. One 
band, corresponding to the size of hNEIL3-843 protein-DNA complex (31.2 kDa + the 
molecular weight of the cleaved DNA substrate and 67.3 kDa + molecular weight of the cleaved 
substrate) can be seen in lanes 3 and 5 respectively. This confirms that the DNA glycosylase 
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activity observed in the activity assays is due to the hNEIL3 proteins and not to contamination 
by the Fpg or Nth proteins of E. coli. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.28  NaBH4-trapping of hNEIL3-843 and hNEIL3-FL on a single-stranded 
oligonucleotide containing a single 5-OHU lesion. 
Lane 1, Molecular weight marker; lane 2, blank; lane 3, hNEIL3-843; lane 4, blank; lane 5, 
hNEIL3-FL. 
 
As a predominant degradation product had been observed during protein purification of 
hNEIL3-FL, it was decided to test the stability of hNEIL3-FL under the reaction conditions 
used. Therefore, the protein was incubated in reaction buffer at 30°C for increasing lengths of 
time, up to 30 min. Figure 4.29 shows that, surprisingly, only one band corresponding to the 
size of hNEIL3-FL is present in each lane and that there is no discernible degradation in any of 
the samples at any of the time points, indicating that the hNEIL3 protein is stable under the 
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reaction conditions used. The result also indicates that the degradation product observed 
throughout the protein purification procedure was removed by the final Amicon concentration 
step while preparing the Mono S fractions for enzyme assays. 
 
 
 
 
 
 
 
 
Figure 4.29  SDS-PAGE of hNEIL3-FL following incubation at 30°C for increasing times in DNA 
glycosylase reaction buffer. 
Duplicate samples of hNEIL3-FL (150 nM) were mixed with the activity assay reaction buffer 
with no oligonucleotides and the samples incubated for 5, 10, 20, and 30 min at 30°C.  
 
 
 
 
 
 
 
 
 
 
kDa 
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4.4.2 Oligonucleotide incision assays. 
To start the biochemical analysis of the recombinant hNEIL3 proteins, it was decided to test 
their DNA glycosylase/lyase activity on ssDNA substrates containing an oxidised pyrimidine 
base at a known position within the sequence, as the murine NEIL3 homologue is known to be 
active on such substrates (Liu et al., 2012). In Figure 4.30, increasing concentrations of 
hNEIL3-843 were incubated at 30ºC or 37ºC for 20 min with a 39 mer ssDNA oligonucleotide 
substrate containing 5-OHU at position 20 to determine optimal reaction conditions for 
subsequent experiments. The results in Figure 4.30 show that incision of the oligonucleotide 
depended on the presence of hNEIL3-843, there being no product band in the control lanes. At 
37ºC cleavage of the substrate appears to be hNEIL3-843 concentration dependent, with the 
highest level of product observed with 600 nM of hNEIL3-843 (lane 5). In contrast, at 30ºC 
there was maximal incision of the substrate oligonucleotide when 300 nM hNEIL3-843 was 
used (lane 3). Based on these results it was decided to use 300 nM hNEIL3-843 and 30ºC for 
subsequent activity assays. 
 
 
 
 
 
Figure 4.30  DNA glycosylase/lyase activity of hNEIL3-843 on 5-OHU in ssDNA at 30ºC and 
37ºC. 
Samples were incubated with increasing concentrations of hNEIL3-843 (0 - 600 nM) for 20 
min at 30ºC (lanes 1 - 4) or 37ºC (lanes 5 – 8). 
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As the incised product in Figure 4.30 is only a small proportion of the amount of substrate on 
the gel and a previous report has found MmNEIL3 to be a monofunctional DNA glycosylase 
(Krokeide et al., 2013) the experiment in Figure 4.30 was repeated at 30°C with the addition of 
NaOH to half the reaction mixtures following the enzyme incubation. Alkali are known to cause 
hydrolysis of abasic sites and therefore the experiment was designed to test if hNEIL3-843 was 
acting primarily as a monofunctional DNA glycosylase, i.e. without the additional AP-lyase 
activity of a bifunctional DNA glycosylase. The result show in Figure 4.31 shows that there 
was little difference in the amount of product obtained after the addition of NaOH to the 
samples, indicating that hNEIL3-843 acts as a bifunctional DNA glycosylase under these 
reaction conditions. However, Figure 4.31 does show that the addition of NaOH increases the 
migration of the product band. This indicates that hNEIL3-843 acts primarily through β-
elimination (leaving a 3ʹ α,β-unsaturated aldehyde) on these substrates while the samples where 
NaOH was added produced a product equivalent to β-δ elimination (a phosphate group at the 
3ʹ-end). 
 
 
 
          
 
 
Figure 4.31 DNA glycosylase / lyase activity of hNEIL3-843 with on 5-OHU in ssDNA +/-NaOH.  
The reaction mixtures were incubated for 20 min at 30ºC. Following incubation, 1 µl of 1 M 
NaOH was added to half the samples (lanes 5 - 8) and heated to 95°C for 3 min and then the 
reaction stopped by the addition of formamide / bromophenol loading buffer. 
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In order to determine the influence of the RanBP zinc finger domain on the activity of hNEIL3 
(Figure 4.33) an oligonucleotide containing 5-OHU was incubated at 30°C with increasing 
concentrations of either hNEIL3-843 or hNEIL3-1044. The result shown in Figure 4.32 
indicates that both proteins are active on the substrate and that the migration of the product is 
the same, suggesting a β-elimination product. Thus, the addition of the RanBP zinc finger 
domain to the DNA glycosylase domain does not affect the enzyme activity in this assay. 
 
 
 
 
 
 
 
 
 
 
Figure 4.32 DNA glycosylase / lyase activity of hNEIL3-843 and hNEIL3-1044 on 5-OHU in 
ssDNA.  
Reactions were incubated for 20 min at 30ºC with increasing amounts of hNEIL3-843 (lanes 1 
– 4) or hNEIL3-1044 (lanes 5 – 8) and the reaction was stopped by the addition of formamide 
/ bromophenol blue loading buffer. 
 
In a similar manner, the DNA glycosylase / lyase activity of hNEIL3-FL was determined 
(Figure 4.33). Increasing concentrations of the purified enzyme were incubated with the 5-OHU 
containing oligonucleotide, with and without the subsequent addition of NaOH Figure 4.33. 
The results indicate that hNEIL3-FL is a bifunctional DNA glycosylase that acts through β-
elimination. Comparison of this result with that for hNEIL3-843 (Figure 4.31) shows an almost 
identical result and indicates that the additional C-terminal domains on the full-length hNEIL3 
appear to have no effect on the DNA glycosylase activity of hNEIL3 on this substrate. 
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Figure 4.33 DNA glycosylase / lyase activity of hNEIL3-FL on 5-OHU in ssDNA +/- NaOH. 
Reactions were incubated for 20 min at 30ºC with increasing concentrations of hNEIL3- FL. 
One microlitre of 1 M NaOH was added to samples 5 -  8 at the end of the reaction and incubated 
at 95°C for 3 min before the addition of formamide / bromophenol blue loading buffer. 
 
 
Next, the DNA glycosylase / lyase activity of hNEIL3-843 on ssDNA substrates containing 
different oxidised bases was analysed (Figure 4.34). The results are shown at two different 
settings of the scanner, as the 5-OHU containing oligonucleotide was labelled with Alexa Fluor 
680 which fluoresces more intensely under the conditions used for the other substrate 
oligonucleotides that were labelled with IRDye700. The results show that hNEIL3-843 is active 
on ssDNA substrates containing 5-OHU or TG, producing a 20 mer product and has a weak 
activity on 8-oxoG, but no activity on the uracil containing substrate (Figure 4.34). Similar 
results were obtained with hNEIL3-FL (Figure 4.35), where again only weak activity was 
observed on 8-oxoG and no activity was evident when uracil was present in the substrate 
oligonucleotide. This again suggests the C-terminal domains had no effect on the DNA 
glycosylase / lyase activity of hNEIL3 on these substrates. 
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Figure 4.34 DNA glycosylase / lyase activity of hNEIL3-843 on single-stranded oligonucleotide 
substrates containing different oxidised bases.  
hNEIL3-843 was incubated for 20 min at 30ºC with ssDNA substrates containing either 5-
OHU, U, TG or 8-oxoG. 
 
 
 
 
 
 
 
Figure 4.35  DNA glycosylase / lyase activity of hNEIL3-FL on single-stranded oligonucleotide 
substrates containing different oxidised bases.  
hNEIL3-FL was incubated for 20 min at 30ºC with ssDNA substrates containing either 5-OHU, 
U, TG or 8-oxoG. 
 
To confirm the results in Figure 4.35, the experiments were repeated with the addition of the 
bacterial DNA glycosylases Nei and Nth as controls and the results quantified (Figure 4.36 and 
Figure 4.37). Figure 4.36 shows that hNEIL3-FL is active on a ssDNA substrate containing 5-
OHU processing 8.4% of the substrate (Figure 4.36A, B) and TG processing 14.3% of the 
substrate (Figure 4.36C and D), but shows only a weak activity on 8-oxoG processing 3.6% of 
the substrate (Figure 4.37A, B) and no activity on uracil with only background levels of 
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fluorescence obtained (Figure 4.37C, D). While detectable levels of incision were obtained for 
Nei on the 5-OHU and TG substrates, no activity was observed with either Nei or Nth on uracil 
or 8-oxoG (Figure 4.37). This agrees with results reported in the literature (Hazra et al., 2000) 
that these bacterial proteins have no, or only minimal activity on ssDNA. Of course, this result 
gives further proof that the observed activity is a result of hNEIL3 action and not from 
contaminating E. coli proteins. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.36 DNA glycosylase / lyase activity of hNEIL3-FL, Nei and Nth on ssDNA substrates 
containing 5-OHU (A, B) and TG (C, D). 
Reactions were incubated for 20 min at 30ºC with hNEIL3-FL (150 nM), Nei (15 nM) or Nth 
(15 nM). 
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Figure 4.37 DNA glycosylase / lyase activity of hNEIL3-FL, Nei and Nth on ssDNA substrates 
containing 8-oxoG (A, B) or uracil (C, D). 
Reactions were incubated for 20 min at 30ºC with hNEIL3-FL (150 nM), Nei (15 nM) or Nth 
(15 nM). 
 
 
To compare the activity of hNEIL3 on single-stranded and double-stranded DNA, hNEIL3-843 
and hNEIL3-FL were incubated for increasing times with either 5-OHU in ssDNA or 5-OHU 
base paired with G in a double-stranded oligonucleotide (Figure 4.38). The result confirms that 
both proteins are active on ssDNA substrates containing 5-OHU but show little or no activity 
on 5-OHU in dsDNA. Furthermore, increasing the incubation time beyond 5 min did not result 
in any increase in product, suggesting that either the substrate was limiting, that the enzyme 
was irreversibly bound to the substrate or product, or that the enzyme had lost activity. In Figure 
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4.38B, no activity was observed for either protein on dsDNA substrates containing a 5-OHU:G 
base pair. 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.38 Time course activity assay of hNEIL3-843 and hNEIL3-FL on ssDNA containing 5-
OHU (A) and dsDNA containing 5-OHU:G (B). 
Reactions were incubated for 5, 10, 20 and 30 min at 30ºC with hNEIL3-843 (lanes 1 – 5) or 
hNEIL3-FL (lanes 6 – 10). 
 
Because the DNA glycosylase/lyase activity of hNEIL3 did not increase after 5 min incubation, 
a time-course experiment was undertaken with a much shorter time-frame. Figure 4.40 shows 
a time-course experiment with a shorter time scale (0, 5, 30, 60, 300 s) using hNEIL3-FL with 
ssDNA and dsDNA substrates containing 5-OHU and 5-OHU:G respectively. The result shows 
increasing activity on the ssDNA substrate up to 300 s (5% of the substrate has been incised, 
(Figure 4.39A, B), and no or very little activity on the dsDNA substrate (2.2% of the substrate 
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incised, (Figure 4.39C, D), A similar result was obtained when TG was substituted for 5-OHU 
(Figure 4.40), with significant incision only observed after 300 s for the ssDNA substrate (5% 
of the substrate incised, (Figure 4.40A, B) and only a minor activity on TG in a dsDNA context 
(1.4% of the substrate incised, (Figure 4.40B), 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.39 Time course activity assay and quantitative analysis of hNEIL3-FL on (A) ssDNA 
substrate containing 5-OHU and (B) dsDNA substrate containing 5-OHU:G.  
Single and double-stranded oligonucleotides containing 5-OHU and 5-OHU:G respectively 
were  incubated for 0, 5, 30, 60 and 300 seconds at 30ºC with hNEIL3-FL. 
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Figure 4.40 Time course activity assay and quantitative analysis of hNEIL3-FL on (A) ssDNA 
substrate containing TG and (B) dsDNA substrate containing TG:A.  
Single and double-stranded oligonucleotides containing TG and TG:A respectively were  
incubated for 0, 5, 30, 60 and 300 seconds at 30ºC with hNEIL3-FL. 
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In order to confirm the activity assays on dsDNA substrates and the mode of action of the 
bifunctional DNA glycosylase activity of hNEIL3, the experiments were repeated with the 
addition of the bacterial Nei (which acts through β/δ-elimination) and Nth (which acts through 
β-elimination) and the results are shown in Figure 4.41. Figure 4.41A confirms a weak activity 
of hNEIL3-FL on 5-OHU when base-paired with G (Figure 4.41B) shows that 2.9% of the 
substrate has been incised). Interestingly, the mode of action is shown to be β/δ-elimination, as 
the product band migrates to the same position as that of Nei (β/δ-elimination) and further than 
that of the product of the Nth (β-elimination) reaction. β/δ-elimination generates a 5ʹ phosphate 
which migrates further in the gel when compared to the 5ʹ PUA generated through β-elimination 
of the phosphodiester backbone. 
Weak activity was also observed for 8-oxoG when base-paired with C (1.6% of the substrate 
has been incised, (Figure 4.41D). Again the product migrates in line with the Nei product, but 
as Nth is not active on the substrate it is not possible to definitively assign a β/δ-elimination 
mechanism to this reaction, although it does seem likely. Finally, hNEIL3-FL showed no 
activity on TG when base-paired with A (0.7% of the substrate has been incised, (Figure 4.41F), 
while the bacterial control proteins both showed good activity on this substrate 
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Figure 4.41 DNA glycosylase / lyase activity and quantitative analysis of hNEIL3-FL, Nei and 
Nth on dsDNA substrates containing either 5-OHU:G (A, B), 8-oxoG:C (C, D), or TG:A (E, F).  
Reactions were incubated at 30ºC for 20 min with either hNEIL3-FL (150 nM), Nei (15 nM) or 
Nth (15 nM). 
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To further examine the activity of hNEIL3-FL on oxidised bases in different contexts in 
dsDNA, the protein was incubated with dsDNA substrates containing 5-OHU, TG, or 8-oxoG 
paired with each of the four possible bases Figure 4.42.  For 5-OHU, weak activity was 
observed when T, C, or G was opposite the oxidised cytosine (Figure 4.42A) This confirms the 
previous finding of weak activity of hNEIL3-FL on 5-OHU:G in Figure 4.41A For TG, the 
strongest activity was observed when paired with C (Figure 4.42B). A more intense band than 
in the control was also observed when TG was paired with A (Figure 4.42B), however, this was 
not routinely observed in subsequent experiments. The presence of a significant product band 
in the no-protein control suggests that this base pair was susceptible to degradation by the 
NaOH treatment alone. For 8-oxoG, weak activity was observed for every base pair, although 
again there was significant product in one of the no-protein controls (8-oxoG:T; (Figure 4.42C). 
These experiments indicate that hNEIL3 could act on oxidised bases in a dsDNA context in 
vivo and further experiments were designed to test this using a model DNA replication fork 
structured DNA oligonucleotide substrates. 
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Figure 4.42 DNA glycosylase / lyase activity of hNEIL3-FL on dsDNA substrates containing 5-
OHU (A), TG (B) and 8-oxoG (C) paired with all four possible bases.  
Reactions were incubated at 30ºC for 20 min with hNEIL3-FL. Following incubation, 1 µl of 1 
M NaOH was added and the reaction stopped by the addition of formamide/bromophenol blue 
loading buffer.  
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4.4.3 Incision of model replication fork substrates containing a single oxidised 
base. 
For the last set of experiments, a model replication fork was designed to test the DNA 
glycosylase / lyase activity of hNEIL3-843 and hNEIL3-FL on oxidised bases in three different 
contexts in the fork. Details of the construct design are given in Table 2.4 but briefly, ‘Fork-4’ 
refers to an oxidised base after the fork in the ssDNA region. ‘Fork’ refers to an oxidised base 
in the last nucleotide in the dsDNA region of the fork, while ‘Fork+4’ refers to an oxidised base 
four nucleotides in front of the fork in the dsDNA. Each Figure shows the activity of hNEIL3 
on these substrates as well as control reactions with the oxidised base in ssDNA, dsDNA and a 
negative control where no protein was added to the reaction. 
 
  
 
 
 
 
 
 
Figure 4.43 DNA glycosylase / lyase activity of hNEIL3-843 on 5-OHU in model replication fork 
substrates.  
hNEIL3-843 was incubated at 30ºC for 20 min with the different substrates. In (A) reactions 
were stopped by the addition of 1 µl of 1 M NaOH, while in (B), the reactions were stopped by 
the addition of formamide / bromophenol blue loading buffer only.  
 
In Figure 4.43 hNEIL3-843 was incubated with the five DNA substrates containing 5-OHU as 
the oxidised base. In Figure 4.43A, NaOH was added after the enzyme reaction to analyse the 
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3ʹ-end of the labelled fragment. In agreement with the results of the initial experiments, 
hNEIL3-843 was most active on 5-OHU in ssDNA (lane 2). Comparison of the two gels also 
confirms that hNEIL3-843 is acting through β-elimination, the product band migrating further 
following NaOH treatment (Figure 4.43A).  In this experiment, activity on the model replication 
fork substrates was weaker than on the ssDNA oligonucleotide, with activity highest when 5-
OHU is in the -4 position (ssDNA) and least in the +4 region (dsDNA). All product bands 
migrate the same distance indicating a similar mode of incision (β-elimination). 
When the experiment was repeated with hNEIL3-FL (Figure 4.44), a similar pattern of incision 
was observed, i.e. the oxidised base in the ssDNA context was the preferred substrate. However, 
strikingly, the incision product of hNEIL3-FL at the +4 position migrates further in the gel than 
the other product bands (Figure 4.44B, lane 6), indicating a β/δ-lyase mode of action. This is in 
contrast to what is observed with hNEIL3-843 (Figure 4.43, lane 6) where the band position is 
in line with β-elimination cleaving product, and is highly reproducible (e.g. Figure 4.45). Figure 
4.45 also confirms the β/δ mode of action as the lower band migrates in line with the product 
of Nei, which has β/δ lyase activity in contrast to the β-elimination mechanism of Nth (Koketsu 
et al., 2004) The same, faster migrating band is also observed when hNEIL3-FL is incubated 
with 5-OHU in a dsDNA oligonucleotide (Figure 4.44, lane 3), however, in Figure 4.44, and to 
a lesser extent in Figure 4.45, the activity of hNEIL3-FL is greater in the context of the model 
replication fork. This is, to my knowledge, the first time the C-terminal domains of hNEIL3 
have been shown to influence the bifunctional DNA glycosylase activity of the protein. 
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Figure 4.44  DNA glycosylase / lyase activity of hNEIL3-FL on 5-OHU in model replication fork 
substrates. 
hNEIL3-FL was incubated at 30ºC for 20 min with the different substrates. The reactions were 
stopped by the addition of formamide/bromophenol blue loading buffer. 
 
 
Figure 4.45 DNA glycosylase / lyase activity (A) and quantitative analysis (B) of hNEIL3-FL on 
5-OHU in model replication fork substrates.  
hNEIL3-FL was incubated at 30ºC for 20 min with the different substrates. The reactions were 
stopped by the addition of formamide/bromophenol blue loading buffer.  
 
To investigate the mechanism of strand incision further, an experiment was performed with 
APE-1 added to the reaction mixture. This would test if the hNEIL3 was acting primarily as a 
monofunctional DNA glycosylase and also help to confirm the β/δ lyase activity observed at 
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the +4 position in the fork in Figure 4.44and Figure 4.45 (6.036% of  5-OHU substrate in +4  
fork position has been incised (Figure 4.45B). The results presented in Figure 4.46 indicate that 
the addition of APE-1 did not affect the method of incision when ssDNA or dsDNA was the 
substrate (lanes 2 & 3), nor did it have any effect when 5-OHU was in the -4 position of the 
model replication fork (lane 3), the banding pattern being almost identical to that in Figure 4.44. 
However, the addition of APE1 did alter the migration of the product band when 5-OHU was 
placed at the fork or at the +4 position, in the dsDNA region. In both, the product band migrates 
between the bands obtained through β− and β/δ- lyase activity and thus indicating the activity 
of APE-1 on the abasic site caused by the monofunctional DNA glycosylase activity of 
hNEIL3-FL. 
 
 
 
 
 
 
 
Figure 4.46 DNA glycosylase / lyase activity of hNEIL3-FL + APE1 on 5-OHU in model 
replication fork substrates.  
Oligonucleotide substrates were incubated at 30ºC for 20 min with NEIL3-FL (300 nM) and 
APE1 (15 nM). 
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Figure 4.47 DNA glycosylase / lyase activity A, B (repeat) and quantitative analysis (C) of 
hNEIL3-843 on TG in model replication fork substrates.  
hNEIL3-843 was incubated at 30ºC for 20 min with the different substrates. Experiment (A) 
was repeated to produce B.  The quantification data was sourced from gel Figure 4.47B. 
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Next, hNEIL3-843 was incubated with the same substrates but containing TG (Figure 4.47). In 
agreement with previous experiments, no activity of hNEIL3-843 was observed on the dsDNA 
substrate (Figure 4.47A, B, lane 3 and Figure 4.41E), but good activity was observed on TG in 
ssDNA (lane 2). Activity at position -4 (ssDNA) on the model replication fork is similar to that 
of the ssDNA oligonucleotide (lanes 2 and 4). The activity at the Fork and position +4 is less 
clear, with one gel showing strong incision activity at position +4 and the other not (39.69% of  
TG substrate in fork +4  position has been incised (Figure 4.47C)). However, comparison with 
Figure 4.49, where the same experiment is shown but with hNEIL3-FL, suggests that hNEIL3 
can act as a bifunctional DNA glycosylase in the double-stranded region of the replication fork 
(compare lane 6 in Figure 4.47and Figure 4.48). 
What is striking about the results in Figure 4.48 is that the mechanism of incision by hNEIL3-
FL at TG is by β-elimination and not β/δ-lyase as observed for 5-OHU. Again this result is 
highly reproducible, only the relative activities at the different positions altering between 
experimental repeats (6.87% of TG substrate in fork +4 position has been incised Figure 4.48C). 
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Figure 4.48 DNA glycosylase / lyase activity A, B (repeat) and quantitative analysis (C) of 
hNEIL3-FL on TG in model replication fork substrates. 
A and B are repeat experiments. hNEIL3-FL was incubated at 30ºC for 20 min with the different 
substrates. The quantification data was sourced from Figure 4.48A. 
 
 
Finally, the experiments were repeated with 8-oxoG as the oxidised base in the model DNA 
replication fork structure. The results, shown in Figure 4.49 and Figure 4.50 are less clear than 
for the oxidised pyrimidines. hNEIL3-843 shows only weak activity against 8-oxoG, 
principally when it is in a ssDNA context (Figure 4.49, lane 2 with  3.28 % of  8-oxoG 
substrate in ssDNA context has been incised Figure 4.49C), However, weak activity can also 
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be observed at both positions -4 and +4 in the fork structure (lanes 4 and 6). This is the first 
evidence that hNEIL3 can release 8-oxoG from dsDNA, albeit a weak activity. Comparison 
with the faint band seen in the Nei lane (lane 7), incision of the abasic site by hNEIL3-843 
appears to be by β-elimination. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.49 DNA glycosylase / lyase activity A, B (repeat) and quantitative analysis (C) of 
hNEIL3-843 on 8-oxoG in model replication fork substrates.  
A and B are repeat experiments. hNEIL3-843 was incubated at 30ºC for 20 min with the 
different substrates. The quantification data was sourced from Figure 4.49A. 
115 
 
 
Activity of hNEIL3-FL on 8-oxoG is also weak, however, significant incision of the dsDNA 
substrate is observed, which is completely lacking in hNEIL3-843 (compare lane 3 in  
Figure 4.49 and Figure 4.50, 2.83 % of  dsDNA 8-oxoG:C substrate has been incised Figure 
4.50C while only 0.29% dsDNA 8-oxoG:C substrate has been incised  
Figure 4.49C). Interestingly, the product band appears to migrate in line with the product of 
Nei, again indicating that the C-terminal domains of hNEIL3 can influence the DNA 
glycosylase / lyase activity of the protein. Also visible in Figure 4.37A,  it is evident that the 
small amount of incision carried out by hNEIL3-FL at the abasic site left after removal of 8-
oxoG, is by β-elimination, similar to what was observed for 5-OHU (Figure 4.44 lane 2). A 
summary of all these findings is given in Table 4.1. 
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Figure 4.50  DNA glycosylase / lyase activity A, B (repeat) and quantitative analysis (C) of 
hNEIL3-FL on 8-oxoG in model replication fork substrates.  
A and B are repeat experiments. hNEIL3-FL was incubated at 30ºC for 20 min with the different 
substrates. The quantification data was sourced from Figure 4.50A. 
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Table 4.1  Summary of hNEIL3 Enzyme Activity. 
Oligonucleotide substrate hNEIL3-843 hNEIL3-FL 
ssDNA(5-OHU) β-elimination β-elimination 
ssDNA(TG) β-elimination β-elimination 
ssDNA(8-oxoG) β-elimination β-elimination 
dsDNA(5-OHU:G) Weak β-elimination Weak β/δ-elimination 
dsDNA(TG:A) No activity No activity 
dsDNA(8-oxoG:C) No activity or weak β-
elimination 
Weak β/δ-elimination 
Fork-4 DNA(5-OHU) β-elimination β-elimination 
Fork DNA(5-OHU) β-elimination β-elimination 
Fork+4 DNA(5-OHU) β-elimination β/δ-elimination 
Fork-4 DNA(TG) β-elimination β-elimination 
Fork DNA(TG) β-elimination β-elimination 
Fork+4 DNA(TG) β-elimination β-elimination 
Fork-4 DNA(8-oxoG) β-elimination β-elimination 
Fork DNA(8-oxoG) β-elimination β-elimination 
Fork+4 DNA(8-oxoG) β-elimination β/δ-elimination 
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5 Discussion  
 
Data presented in this thesis show successful expression and purification of full-length and 
truncated versions of the human NEIL3 protein in an active form. The recombinant proteins 
have been characterised using enzyme activity assays, using different oxidised bases in ssDNA, 
dsDNA and in different positions in a replication fork context. The results obtained give an 
insight into the role of hNEIL3 in the repair of oxidised DNA base damage during the 
replication process. Furthermore, when comparing the activity of the truncated DNA 
glycosylase only domain (hNEIL3-843) and hNEIL3-FL, data shows that the C-terminal tail of 
NEIL3 has an influence on the AP lyase activity of the hNEIL3 protein and that hNEIL3-FL 
uniquely acts through both β-elimination and/or β,δ-elimination AP lyase activity, and that this 
is dependent on the substrate lesion and the position of the oxidised base at the replication fork.  
 
Human NEIL3 has been reported to be difficult to express in E. coli and this has limited the 
biochemical characterization and functional studies of the protein in order to understand its role 
in cell survival (Liu et al, 2012). The expression vector pETDuet-2 was first described by Liu 
et al. (2012) and used to express active murine NEIL3 protein. This vector possesses two 
significant parts, one is a short sequence, ORF6, in front of the coding sequence of NEIL3, and 
the other is an engineered version of the E. coli amino peptidase, EcoMapY168A that has 
greater activity on the N-terminal methionine in hNEIL3 than the endogenous enzyme. The 
expression vector also possesses a six-histidine fusion tag downstream of the target gene that 
allows protein purification using affinity chromatography (Liu et al, 2012). 
 
The first aim of the project was to express both full-length and truncated versions of hNEIL3 
using the pETDuet-2 expression system to allow their biochemical characterisation in a number 
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of different assays. In this way it was hoped that the role of the extended C-terminal domains 
can be determined through their interaction with different DNA substrates. 
 
Cloning of mouse NEIL3 into the pETDuet-2 expression vector was achieved by amplifying 
mouse NEIL3 cDNA and adding NdeI and XhoI restriction sites to the forward and reverse 
primers respectively, then digesting the PCR product with NdeI and XhoI and cloning the 
digested cDNA into the pETDuet-2 expression vector by linearizing the vector with the same 
restriction enzymes to create compatible ends (Liu et al., 2012). For hNEIL3, this cloning 
strategy could be used for the hNEIL3-843 truncation only. For the ORF6-hNEIL3-1044, 1236, 
1506 and full-length cDNAs, direct cloning into the pETDuet2 expression vector using an NdeI 
and XhoI double-digest was not possible because hNEIL3 possesses an NdeI restriction site at 
position 864 bp. This means that the NdeI enzyme cuts the hNEIL3 cDNA preventing cloning 
of any longer hNEIL3 fragment into the pETDuet2 expression vector. To overcome this 
obstacle, a different cloning strategy had to be designed. Due to destruction of the EcoRV site 
in pETDuet2 during the construction of the vector, and the presence of multiple EcoRV 
restriction sites in the EcoMapY168A DNA sequence, the double-stranded ORF6 sequence was 
synthesised (Eurofins) and ligated into pET30-b (Balis, 2013). Therefore, the ORF6-hNEIL3 
inserts were first constructed in pET30-b-ORF6 and then transferred to the pETDuet-2 
expression vector.  
 
After cloning the hNEIL3 inserts into the pET30b-ORF6 vector was achieved and confirmed, 
a novel strategy was used to clone the ORF6-hNEIL3 inserts into pETDuet-2 expression vector. 
An ORF6-hNEIL3 forward primer was designed to amplify ORF6-hNEIL3 inserts from 
pET30b-ORF6-hNEIL3 then the PCR products were digested with XhoI to create a XhoI site 
compatible with the XhoI site in the expression vector. The pETDuet-2 expression vector was 
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prepared for cloning in three steps, first the vector was linearized by NdeI restriction enzyme 
digest, second the NdeI site overhang resulting from the NdeI restriction digest was removed 
using mung bean nuclease and finally the vector was digested with XhoI. By the end of this 
process compatible ends for cloning ORF6-hNEIL3 inserts in the correct reading frame into the 
pETDuet-2 expression vector were created. 
 
Human NEIL3 protein expression in E. coli was carried out starting with test protein expression 
of pETDuet-2-ORF6-hNEIL3 (843, 1044, 1506 and full length) using a modified protein 
expression protocol of Liu et al. (2012). Different incubation times (3 h and 18 h) and 
temperatures (16°C and 37°C) were tried after inducing the E. coli cultures with 1 mM IPTG. 
Protein was extracted and recombinant hNEIL3 expression, confirmed by SDS-PAGE and 
western blotting, before hNEIL3 was expressed using larger E. coli cultures (300 ml) induced 
with IPTG and incubated at 16°C for 18 h. The His-tagged proteins were then purified and the 
expression and purification of hNEIL3-(843, 1044, 1506 and full length) was confirmed by 
SDS-PAGE and western blotting. 
 
The SDS-PAGE and western blotting results, following the His-Trap FPLC purification of 
hNEIL3-(843 and 1044) purified proteins confirmed that the proteins were pure enough to carry 
out the enzyme activity assays. However, for hNEIL3-FL, expression and purification was 
repeated using larger cultures (1200 ml) and the same expression protocol was followed. The 
protein was purified using His-Trap chromatography (Section 3.2.3) and fractions were tested 
by SDS-PAGE and western blotting and subsequently underwent further purification using 
Mono S FPLC (Section 3.2.5). At the end of the expression and purification process the 
successful expression and purification of recombinant hNEIL3-(843, 1044 and FL) was 
confirmed by SDS-PAGE and western blotting. 
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In order to characterize the purified recombinant hNEIL3-(843, 1044 and FL) proteins, hNEIL3 
proteins were tested by enzyme activity assays to determine their DNA glycosylase / AP lyase 
activity. Both hNEIL3-843 and hNEIL3-FL were also subjected to a NaBH4-trapping assay and 
the result proved that the observed activity was due to the recombinant proteins (Figure 4.28). 
The stability of hNEIL3-FL during the activity assays was also tested and the protein proved to 
be stable under the reaction conditions (Figure 4.29). 
 
The biochemical analysis of the recombinant hNEIL3 proteins was assessed by incubating the 
purified proteins with oligonucleotides containing a single oxidised base. In order to test their 
DNA glycosylase / AP lyase activity, a 39 mer ssDNA oligonucleotide substrate containing 5-
OHU at position 20 was initially used. The reaction was carried out at 30ºC or 37ºC for 20 min 
to determine the optimal reaction conditions (Figure 4.30). All three hNEIL3 proteins proved 
to be active on the substrate using 300 nM of the proteins. The observed activity of the 
recombinant hNEIL3 proteins on the ssDNA oligonucleotide substrate was through β-
elimination, as when the proteins were tested in the presence of NaOH, the addition of NaOH 
produced product bands equal to β/δ elimination. The results were similar for all hNEIL3 
proteins (843, 1044 and FL), indicating that the hNEIL3-FL is a bifunctional DNA glycosylase 
that acts predominantly through β-elimination and the C-terminal domain in hNEIL3-FL has 
no effect on those substrates under these reaction conditions. 
 
At this point it was decided to proceed with enzyme activity assays for hNEIL3-843, which 
contains the N-glycosylase domain and hNEIL3-FL which contains all the protein domains.  
The DNA glycosylase / AP lyase activity of hNEIL3-843 and hNEIL3-FL on ssDNA substrates 
containing different oxidised bases (5-OHU, TG, 8-oxoG and U) was tested and both proteins 
122 
 
proved to be active on ssDNA substrates containing 5-OHU or TG acting through β-
elimination, while only weak activity was observed on 8-oxoG and no activity on the uracil 
containing substrate. The experiments were repeated with the addition of the bacterial DNA 
glycosylases Nei and Nth as positive controls to confirm β,δ (Nei) and β-elimination (Nth) 
reaction products. 
 
Time course experiments were carried out to determine the time needed to complete the 
reaction, the results show that the maximum percentage of 20 mer cleaved product is reached 
in 5 min. The DNA glycosylase / AP lyase activity of the recombinant hNEIL3 proteins were 
then tested on double-stranded oligonucleotides containing a single oxidised base (5-OHU:G, 
TG:A and 8-oxoG:C), the result show weak activity on double-stranded oligonucleotides 
containing (5-OHU:G and  TG:A) and no activity on the substrate containing (8-oxoG:C). 
 
The hNEIL3 recombinant proteins were then tested on a model replication fork that was 
designed with the oxidised base in three different positions (Table 2.4): (i) at position -4, the 
oxidised base resides after the fork, in a ssDNA context, (ii) in ‘Fork’ the oxidised base is the 
last nucleotide in the dsDNA region of the fork, and (iii) at +4 the oxidised base position is four 
nucleotides in front of the fork in the dsDNA.  
 
In Figure 4.43, the results show that hNEIL3-843 is most active on the ssDNA substrate 
containing 5-OHU confirming the previous results with high activity on 5-OHU in the Fork-4 
position (ssDNA) and least activity in the +4 region (dsDNA) and acting through β-elimination. 
However, while hNEIL3-FL shows a similar pattern of incision for the 5-OHU containing 
ssDNA substrate and Fork-4 position (ssDNA), with 5-OHU at the Fork+4 position (dsDNA), 
the product band migrates further in the gel and in line with the product of Nei incision (Figure 
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4.45), indicating that hNEIL3-FL is acting through β,δ-lyase mode of action on those substrates. 
A similar faster migrating, but weaker, band is also observed when hNEIL3-FL is incubated 
with 5-OHU in a dsDNA oligonucleotide, but the activity is greater when the oxidised base is 
at the Fork+4 position (dsDNA) in the model replication fork. This indicates, for the first time, 
that the C-terminal domains of hNEIL3 have an effect on the mechanism of the bifunctional 
DNA glycosylase activity of the protein. 
 
These experiments were repeated on the same model replication fork substrates but containing 
TG; for hNEIL3-843 the results were in agreement with the 5-OHU substrates while, in 
contrast, hNEIL3-FL acts through β-elimination in all of the TG substrates and not β/δ-lyase as 
observed for 5-OHU (Figure 4.48). The experiments were also repeated using substrates 
containing 8-oxoG, but hNEIL3-843 showed only weak activity on ssDNA and at both Fork-4 
and Fork+4 positions in the replication fork structure (Figure 4.49). Comparison with the 
product of Nei incision, indicates that hNEIL3-843 incised the abasic site through β-elimination 
(Figure 4.49). 
 
For hNEIL3-FL activity on 8-oxoG, the results again show only weak activity in a ssDNA 
context and incision by β-elimination (Figure 4.50). However, in both repeats there is 
significant incision of the 8-oxoG containing oligonucleotide at the Fork+4 position and the 
incision is through β,δ lyase activity (Figure 4.50). This incision activity was essentially absent 
when hNEIL3-843 was used (lane 3 in Figure 4.49 and Figure 4.50). Thus these results are in 
agreement with the hNEIL3-FL activity observed for 5-OHU and confirm that the C-terminal 
domains of hNEIL3 can influence the DNA glycosylase / AP lyase activity of the protein. 
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NEIL3 is normally expressed in specific highly proliferating cells, however, cancer cells 
commonly display overexpression of NEIL3. As NEIL3 expression is highest in the S and G2 
phases of the cell cycle, this suggested a role in the maintenance of successful DNA replication. 
Data presented here shows that hNEIL3 undertakes DNA glycosylase and AP-lyase activity 
dependent on the lesion position or type of the substrate (TG always β and 5-OHU β or β,δ-
elimination), and that the C-terminal domain of NEIL3 has influence on the type of the 
bifunctional lyase activity of the NEIL3 protein. 
 
Here it is shown that, of the three substrate lesions tested, NEIL3 has a preference for DNA 
containing 5-OHU and TG, oxidised bases that are also processed by NEIL1, NEIL2 and NTH1 
(Wallace, 2014). However, the finding that NEIL3 is expressed during the S/G2-phases of the 
cell cycle suggests that NEIL3 has a role of recognizing and removing oxidative lesions during 
DNA replication particularly at the replication fork. NEIL1 is also reported to be cell cycle 
regulated with the highest activity found during S-phase (Hazra and Mitra, 2006). 
Complementary data obtained in our lab (Albelazi et al. in preparation) indicates efficient 
activity of hNEIL1 on 5-OHU and TG in dsDNA and dsDNA close to the replication fork, 
while NEIL3 shows preference for ssDNA and ssDNA in the model replication fork, with no 
activity in dsDNA containing TG, suggesting that NEIL1 and NEIL3 have overlapping and 
complementary functions in the repair of oxidized bases at the replication fork. 
 
While NEIL3 shows only weak or no activity on DNA substrates containing 8-oxoG, NEIL3 is 
active on the further oxidation products of 8-oxoG, Sp and Gh (Krokeide et al., 2013), although 
NEIL1 has been reported to show greater activity on those substrates in enzyme activity assays 
(Krokeide et al., 2013; Martin et al., 2017). On the other hand, Krokeide et al. (2013) showed 
that NEIL3 incised oxidised DNA lesions by β-elimination unlike NEIL1 and NEIL2, which 
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act through β,δ-elimination. Data presented here show that NEIL3 also possesses a β,δ-
elimination mode of action depending on the damaged base type and position in the model 
replication fork. 
 
In recently published work, the lack of NEIL3 led to telomere dysfunction causing anaphase 
bridges (Zhou et al., 2017). Also, it has been shown that NEIL3 has a role in the repair of ICLs 
(Semlow et al., 2016; Klattenhoff et al., 2017; Martin et al., 2017).  Along with the bacterial 
homolog Nei, NEIL1 and NEIL3 can unhook three- and four-stranded psoralen-induced ICL 
structures by hydrolysis of the glycosylic bond between the base and deoxyribose sugar. 
Uniquely, hNEIL3 achieved this through a mechanism that did not generate toxic double-strand 
breaks and therefore subsequent activation of the DNA damage response pathway and potential 
deleterious consequences to the cell (Martin et al., 2017). 
Thus, the overexpression of hNEIL3 in cancer cells may give them a growth advantage and 
could be vital during S phase in relation to the repair of the DNA replication thus safe guarding 
the genomic integrity of the newly synthesised DNA in daughter cells. Taken together, all this 
data suggests that the inhibition of hNEIL3 activity in cancer cells may be a good target to 
overcome the resistance of some cancer cells to specific genotoxic agents that are commonly 
used in cancer therapy to induce ICLs in DNA. 
 
Thus, data presented here supports a role for hNEIL3 as a bifunctional DNA glycosylase, 
particularly in DNA replication, with AP lyase activity on oxidized bases within ssDNA and 
dsDNA at the replication fork either through β or β,δ-elimination depending on the context of 
the oxidised base lesion. This activity is, to my knowledge, unique to NEIL3 as all other 
bifunctional DNA glycosylases act through either β-elimination or β,δ-elimination alone. 
Furthermore, work presented here, and that performed subsequently using the recombinant 
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proteins discussed in this thesis, have shown that hNEIL1 and hNEIL3 have complementary 
roles at the DNA replication fork, both in the release of oxidised pyrimidines and in the 
resolution of ICLs. Further work is now required to examine the control of hNEIL3 levels in 
cells, the proteins it interacts with and the effect of reducing or deleting hNEIL3 in specific 
cells to determine any increased efficacy of clinically relevant genotoxic cancer agents. 
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7 Appendix 
 
7.1 Human Neil3-FL Sequence results 
CATATGAAAATCGAAGCAGGTAAACTGGTACAGAAGGAGATTAACTGATGGTGGAAGGAC
CAGGCTGTACTCTGAATGGAGAGAAGATTCGAGCGCGGGTGCTCCCGGGCCAGGCGGTGACCG
GCGTGCGGGGAAGCGCTCTGCGGAGTCTGCAGGGCCGCGCCTTGCGGCTCGCAGCCTCCACG
GTTGTGGTCTCCCCGCAGGCTGCTGCACTGAATAATGATTCCAGCCAGAATGTCTTGAGCCTGTT
TAATGGATATGTTTACAGTGGCGTGGAAACTTTGGGGAAGGAGCTCTTTATGTACTTTGGACCAA
AAGCTTTACGGATTCATTTCGGAATGAAAGGCTTCATCATGATTAATCCACTTGAGTATAAATATAA
AAATGGAGCTTCTCGTGTTTTGGAAGTGCAGCTCACCAAAGATTTGATTTGTTTCTTTGACTCATC
AGTAGAACTCAGAAACTCAATGGAAAGCCAACAGAGAATAAGAATGATGAAAGAATTAGATGTAT
GTTCACCTGAATTTAGTTTCTTGAGAGCAGAAAGTGAAGTTAAAAAACAGAAAGGCCGGATGCTA
GGTGATGTGCTAATGGATCAGAACGTATTGCCTGGAGTAGGGAACATCATCAAAAATGAAGCTCT
CTTTGACAGTGGTCTCCACCCAGCTGTTAAAGTTTGTCAATTAACAGATGAACAGATCCATCACCT
CATGAAAATGATACGTGATTTCAGCATTCTCTTTTACAGGTGCCGTAAAGCAGGACTTGCTCTCTC
TAAACACTATAAGGTTTACAAGCGTCCCAATTGTGGTCAGTGCCACTGCAGAATAACTGTGTGCC
GCTTTGGGGACAATAACAGAATGACATATTTCTGTCCTCACTGTCAAAAAGAAAATCCTCAACATG
TTGACATATGCAAGCTACCGACTAGAAATACTATAATCAGTTGGACATCTAGCAGGGTGGATCAT
GTTATGGACTCCGTGGCTCGGAAGTCGGAAGAGCACTGGACCTGTGTGGTGTGTACTTTAATCAA
TAAGCCCTCTTCTAAGGCATGTGATGCTTGCTTGACCTCAAGGCCTATTGATTCAGTGCTCAAGA
GTGAAGAAAATTCTACTGTCTTTAGCCACTTAATGAAGTACCCGTGTAATACTTTTGGAAAACCTC
ATACAGAAGTCAAGATCAACAGGAAAACTGCATTTGGAACTACAACTCTTGTCTTGACTGATTTTA
GCAATAAATCCAGTACTTTGGAAAGAAAAACAAAGCAAAACCAGATACTAGATGAGGAGTTTCAAA
ACTCTCCTCCTGCTAGTGTGTGTTTGAATGATATACAGCACCCCTCCAAGAAGACAACAAACGATA
TAACTCAACTATCCAGCAAAGTAAACATATCACCTACAATCAGTTCAGAATCTAAATTATTTAGTCC
AGCACATAAAAAACCGAAAACAGCCCACTACTCATCACCAGAGCTTAAAAGCTGCAACCCTGGAT
ATTCTAACAGTGAACTTCAAATTAATATGACAGATGGCCCTCGTACCTTAAATCCTGACAGCCCTC
GCTGCAGTAAACACAACCGCCTCTGCATTCTCCGAGTTGTGAGGAAGGATGGGGAAAACAAGGG
CAGGCAGTTTTATGCCTGTCCTCTACCTAGAGAAGCACAATGTGGATTTTTTGAATGGGCAGATTT
138 
 
GTCCTTCCCATTCTGCAACCATGGCAAGCGTTCCACCATGAAAACAGTATTGAAGATTGGACCTA
ACAATGGAAAGAATTTTTTTGTGTGTCCTCTTGGGAAGGAAAAACAATGCAATTTTTTCCAGTGGG
CAGAAAATGGGCCAGGAATAAAAATTATTCCTGGATGCTAACTCGAGCACCACCACCACCA
CCAC 
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hNEIL3 FL forward  
>FR07649289 
CTATAGGGGATTGTGAGCGGATAACAATTCCCCATCTTAGTATATTAGTTAAGTATAAGA
AGGAGATATACATATGAAAATCGAAGCAGGTAAACTGGTACAGAAGGAGATTAACTGAT
GGTGGAAGGACCAGGCTGTACTCTGAATGGAGAGAAGATTCGAGCGCGGGTGCTCCCGG
GCCAGGCGGTGACCGGCGTGCGGGGAAGCGCTCTGCGGAGTCTGCAGGGCCGCGCCTTG
CGGCTCGCAGCCTCCACGGTTGTGGTCTCCCCGCAGGCTGCTGCACTGAATAATGATTCC
AGCCAGAATGTCTTGAGCCTGTTTAATGGATATGTTTACAGTGGCGTGGAAACTTTGGGG
AAGGAGCTCTTTATGTACTTTGGACCAAAAGCTTTACGGATTCATTTCGGAATGAAAGGC
TTCATCATGATTAATCCACTTGAGTATAAATATAAAAATGGAGCTTCTCGTGTTTTGGAAG
TGCAGCTCACCAAAGATTTGATTTGTTTCTTTGACTCATCAGTAGAACTCAGAAACTCAAT
GGAAAGCCAACAGAGAATAAGAATGATGAAAGAATTAGATGTATGTTCACCTGAATTTA
GTTTCTTGAGAGCAGAAAGTGAAGTTAAAAAACAGAAAGGCCGGATGCTAGGTGATGTG
CTAATGGATCAGAACGTATTGCCTGGAGTAGGGAACATCATCAAAAATGAAGCTCTCTTT
GACAGTGGTCTCCACCCAGCTGTTAAAGTTTGTCAATTAACAGATGAACAGATCCATCAC
CTCATGAAAATGATACGTGATTTCAGCATTCTCTTTTACAGGTGCCGTAAAGCAGGACTT
GCTCTCTCTAAACACTATAAGGTTTACAAGCGTCCCAATTGTGGTCAGTGCCACTGCAGA
ATAACTGTGTGCCGCTTTGGGGACAATAACAGAATGACATATTTCTGTCCT 
hNEIL3-FLength reverse  
>FR07649198 
CTACACAGTGAGATCTCGCAATTCCGAAAAATAAACAATATGACTCCGTCCTCGGTGGGA
TACTTAAAGCATTACGGCCCATCTTACTATAGTACATGTGACTGTTAGGCTAGCACTCAA
GGCTTATAGGATTCAATGATCAAAGACAGAAGAAAAGATTTTATCGTACATTGCCCACGT
CAGTGAAGGGCTCGGGTGATTATGTTTGAAAACCTCGATGCAGATGTCGAGATCAACAAT
GACAGTACAATTGGAATCTACAGCTCTGGTATTTGATGATTTTAGGCAATAAATGCGATA
TTTAGTAAGGCAAGACACAGCAAAGCCCGTTATATGATGAGGAGTTCCAAGACTCTCCTC
140 
 
GAGCTAGGGTGTGGTTGGATGAGATCCAGCACCCATCCAAGAAGACAACAAACGATATA
ACTCACCTGTCCAGCAAAGTAAACATATCACGGACAATCAGTTCAGAATATAAATCATTT
AGTCCAGCACAAAAAAAACCGAAAACAGCCCAGTACTCATCACCAGAGATTAAAAGCTG
CATCCACGGATATTCTAACAGTGAACTTCAAATTAATATGACGGATGGCCCTCGTACCTT
AAATCCTGACAGCCCTCGCTGCAGTAAACACAACCGCCTCTGCATTCTAGGAGTTGTGAG
GAAGGATGGGGAAAACAAGGGCAGGCAGTTTTATGCCTGTCCTCTGCCTAGAGAAGCAC
AACGTGGATTTTTTGAATGGGCAGATTTGTCCTTCCCTTTCTGCAACCAAGGCAAGAGTTC
CACCATGATAACAGTATTGAAGATTGGCCGTAACAATGGAAAGAATTTTTTTGTGTGTCC
TCTTGGGAGGGAAAAACAATGCAATTTTTTCCAGTGGGCAGAAAATGGGCCAGGAATAA
AAAGTATTCCTGGACGCCTCGAGCACCACCACCACCACCACTGAGATCCGGCTGCTAACA
AAGCCTTTAAAGTATTATTGGGTTTTC 
 
hNEIL3-1506 forward  
>FR07649287 
TAGGGGATTGTGAGCGGATAACAATTCCCCATCTTAGTATATTAGTTAAGTATAAGAAGG
AGATATACATATGAAAATCGAAGCAGGTAAACTGGTACAGAAGGAGATTAACTGATGGT
GGAAGGACCAGGCTGTACTCTGAATGGAGAGAAGATTCGAGCGCGGGTGCTCCCGGGCC
AGGCGGTGACCGGCGTGCGGGGAAGCGCTCTGCGGAGTCTGCAGGGCCGCGCCTTGCGG
CTCGCAGCCTCCACGGTTGTGGTCTCCCCGCAGGCTGCTGCACTGAATAATGATTCCAGC
CAGAATGTCTTGAGCCTGTTTAATGGATATGTTTACAGTGGCGTGGAAACTTTGGGGAAG
GAGCTCTTTATGTACTTTGGACCAAAAGCTTTACGGATTCATTTCGGAATGAAAGGCTTCA
TCATGATTAATCCACTTGAGTATAAATATAAAAATGGAGCTTCTCGTGTTTTGGAAGTGC
AGCTCACCAAAGATTTGATTTGTTTCTTTGACTCATCAGTAGAACTCAGAAACTCAATGG
AAAGCCAACAGAGAATAAGAATGATGAAAGAATTAGATGTATGTTCACCTGAATTTAGTT
TCTTGAGAGCAGAAAGTGAAGTTAAAAAACAGAAAGGCCGGATGCTAGGTGATGTGCTA
ATGGATCAGAACGTATTGCCTGGAGTAGGGAACATCATCAAAAATGAAGCTCTCTTTGAC
AGTGGTCTCCACCCAGCTGTTAAAGTTTGTCAATTAACAGATGAACAGATCCATCACCTC
141 
 
ATGAAAATGATACGTGATTTCAGCATTCTCTTTTACAGGTGCCGTAAAGCAGGACTTGCT
CTCTCTAAACACTATAAGGTTTACAAGCGTCCCAATTGTGGTCAGTGCCACTGCAGAATA
ACTGTGTG 
hNEIL3 (1506) reverse 
>FR07649197 
TCAGTTTCTTTTGACGAACACGTGTTGACTTATCGTACGGATCGCACGGGCTGTTTGTACA
GGCTTCAGCTCCAATTGCATGTCAGCATGCGTCATGGATGCCAGTCGTGTTTACTGCATAT
CTGCTTCGTTCATTTCAGCATGCTCTCTTACCACGTGCTGTAAAAGCAGGTCTTGCTCTAT
CTTAACCATATAATGATTACTAAGTGTCTCACTTGTGATCAGTACATACCGGATTATCTTG
TGAGTCTTCTTTGAGAACAATTAACAGAATGACATAGTTCTGTGCTCACTGTCACAAAGA
AATATCATAAACATGTTACATATGCAAGCTACACGAGTAGAAATACCTATAATCAGTTGG
ACATCTAACCAGGGTTGGATCATGTTATGGAATCCGTGGCTCGGAAGTCGGAAGAGCTCT
GGACTCTGTGTGGTGTGTACTTTAATCAATAAGCCCTCTTATAAGGCCATGTGATGCTTGC
TTGACCTCAAGGCCTATTGATTCAGTGCTCAAGAGTGAAGAAAATTCTACTGTCTTTAGCC
ACTTAATGAAGTACCCGTGTAATACTTTTGGAAAACCTCATACAGAAGTCAAGATCAACA
GGAAAACTGCATTTGGAACTACAACTCTTGTCTTGACTGATTTTAGCAATAAATCCAGTA
CTTTGGAAAGAAAAACAAAGCAAAACCAGATACTAGATGAGGAGTTTCAAAACTCTCCT
CCTGCTAGTGTGTGTTTGAATGATATACAGCACCCCTCCAAGAAGACAACAAACGATATA
ACTCAACTATCCAGCAAAGTAAACATATCACCTACAATCAGTTCAGAATCTAAATTATTT
AGTCCAGCACATAAAAAACCGAAAACAGCCCACTACTCATCACCAGAGCTTAAAAGCTG
CAACCCTGGATATTCTAACAGTGAACTTCAAATTAATATGACAGATGGCCCTCGTACCTT
AAATCCTCTCGAGCACCACCACCACCACCACTGAGATCCGGCTGCTAACAAAGCCCGAAA
GAGTATTGCCCCCGAACCCCAAAAAACAACCTT 
 
 
 
142 
 
hNEIL3-1044 forward 
>FR07649286 
ATAGGGGATTGTGAGCGGATAACAATTCCCCATCTTAGTATATTAGTTAAGTATAAGAAG
GAGATATACATATGAAAATCGAAGCAGGTAAACTGGTACAGAAGGAGATTAACTGATGG
TGGAAGGACCAGGCTGTACTCTGAATGGAGAGAAGATTCGAGCGCGGGTGCTCCCGGGC
CAGGCGGTGACCGGCGTGCGGGGAAGCGCTCTGCGGAGTCTGCAGGGCCGCGCCTTGCG
GCTCGCAGCCTCCACGGTTGTGGTCTCCCCGCAGGCTGCTGCACTGAATAATGATTCCAG
CCAGAATGTCTTGAGCCTGTTTAATGGATATGTTTACAGTGGCGTGGAAACTTTGGGGAA
GGAGCTCTTTATGTACTTTGGACCAAAAGCTTTACGGATTCATTTCGGAATGAAAGGCTTC
ATCATGATTAATCCACTTGAGTATAAATATAAAAATGGAGCTTCTCGTGTTTTGGAAGTG
CAGCTCACCAAAGATTTGATTTGTTTCTTTGACTCATCAGTAGAACTCAGAAACTCAATGG
AAAGCCAACAGAGAATAAGAATGATGAAAGAATTAGATGTATGTTCACCTGAATTTAGTT
TCTTGAGAGCAGAAAGTGAAGTTAAAAAACAGAAAGGCCGGATGCTAGGTGATGTGCTA
ATGGATCAGAACGTATTGCCTGGAGTAGGGAACATCATCAAAAATGAAGCTCTCTTTGAC
AGTGGTCTCCACCCAGCTGTTAAAGTTTGTCAATTAACAGATGAACAGATCCATCACCTC
ATGAAAATGATACGTGATTTCAGCATTCTCTTTTACAGGTGCCGTAAAGCAGGACTTGCT
CTCTCTAAACACTATAAGGTTTACAAGCGTCCCAATTGTGGTCAGTGCCACTGCAGAATA
ACTGTGTGCCGCTTTGGGGACAATAACAGAATGACATATTTCTGTCCTCACTGTCAAAAA
AAAATCCTCA 
hNEIL3-1044 reverse  
>FR07649196 
GGAGTGCAGGCTCACCTAAGATTTTATTGATTTCTTTGCAGTCAGCAGCAGAATTCAGAA
ATGTCAATGATAAGCCTCCAGAGACTAGAGAGTGATGACAGATTCAGATGTATGTTCACA
TGAATTTAGTTTCAAGAGAGCAGAAAGTGAAGTTAAAAAACAGAAAAGGCCAGATGAAA
GGTGATGTGCTAATGGATCGGAACGTATTGCCCGGAGTAGGGAACATCATCAAAAATGA
AGCTCTCTTTGACAGTGGTCTCCACCTAGCTGTTAAAGTTTGTCAATTAACAGATGAACAG
143 
 
ATCCATCACCTCATGAAAATGATACGTGATTTCAGCATTCTCTTTTACGGGTGCCGTAAAG
CAGGACTTGCTCTCTCTAAACACTATAAGGTTTACAAGCGTCCCAATTGTGGTCAGTGCC
ACTGCAGAATAACTGTGTGCCGCTTTGGGGACAATAACAGAATGACATATTTCTGTCCTC
ACTGTCAAAAAGAAAATCCTCAACATGTTGACATATGCAAGCTACCGACTAGAAATACTA
TAATCAGTTGGACATCTAGCAGGGTGGATCATGTTATGGACTCCGTGGCTCGGAAGTCGG
AAGAGCACTGGACCTGTGTGGTGTGTACTTTAATCAATAAGCCCTCTTGTAAGGCATGTG
ATGCTTGCTTGACCTCAAGGCCTATTGATTCACTCGAGCACCACCACCACCAACCAGTGA
GATCCGGCTGCTAACAAAGCCCCGGAACGCTAAAAAGGGGGTCCCCCC 
 
hNEIL3-843 forward  
>FR07649194 
GATTGTGAGCGGATAACAATTCCCCATCTTAGTATATTAGTTAAGTATAAGAAGGAGATA
TACATATGAAAATCGAAGCAGGTAAACTGGTACAGAAGGAGATTAACTGATGGTGGAAG
GACCAGGCTGTACTCTGAATGGAGAGAAGATTCGAGCGCGGGTGCTCCCGGGCCAGGCG
GTGACCGGCGTGCGGGGAAGCGCTCTGCGGAGTCTGCAGGGCCGCGCCTTGCGGCTCGC
AGCCTCCACGGTTGTGGTCTCCCCGCAGGCTGCTGCACTGAATAATGATTCCAGCCAGAA
TGTCTTGAGCCTGTTTAATGGATATGTTTACAGTGGCGTGGAAACTTTGGGGAAGGAGCT
CTTTATGTACTTTGGACCAAAAGCTTTACGGATTCATTTCGGAATGAAAGGCTTCATCATG
ATTAATCCACTTGAGTATAAATATAAAAATGGAGCTTCTCGTGTTTTGGAAGTGCAGCTC
ACCAAAGATTTGATTTGTTTCTTTGACTCATCAGTAGAACTCAGAAACTCAATGGAAAGC
CAACAGAGAATAAGAATGATGAAAGAATTAGATGTATGTTCACCTGAATTTAGTTTCTTG
AGAGCAGAAAGTGAAGTTAAAAAACAGAAAGGCCGGATGCTAGGTGATGTGCTAATGGA
TCAGAACGTATTGCCTGGAGTAGGGAACATCATCAAAAATGAAGCTCTCTTTGACAGTGG
TCTCCACCCAGCTGTTAAAGTTTGTCAATTAACAGATGAACAGATCCATCACCTCATGAA
AATGATACGTGATTTCAGCATTCTCTTTTACAGGTGCCGTAAAGCAGGACTTGCTCTCTCT
AAACACTATAAGGTTTACAAGCGTCCCAATTGTGGTCAGTGCCACTGCAGAATAACTGTG
144 
 
TGCCGCTTTGGGGACCATAACAGAATGACATATTTCTGTCCTCACTGTCAAAAACTCGAG
CACCACCACCACCACCACTGAAATCCGGCTGCTAACAAAGCCCGAAAGGAAAC 
 
hNEIL3-843 reverse 
>FR07649195 
GAGAAGATTCGAGCGCGGGTGCTCCCGGGCCAGGCGGTGACCGGCGTGCGGGGAAGCGC
TCTGCGGAGTCTGCAGGGCCGCGCCTTGCGGCTCGCAGCCTCCACGGTTGTGGTCTCCCC
GCAGGCTGCTGCACTGAATAATGATTCCAGCCAGAATGTCTTGAGCCTGTTTAATGGATA
TGTTTACAGTGGCGTGGAAACTTTGGGGAAGGAGCTCTTTATGTACTTTGGACCAAAAGC
TTTACGGATTCATTTCGGAATGAAAGGCTTCATCATGATTAATCCACTTGAGTATAAATAT
AAAAATGGAGCTTCTCGTGTTTTGGAAGTGCAGCTCACCAAAGATTTGATTTGTTTCTTTG
ACTCATCAGTAGAACTCAGAAACTCAATGGAAAGCCAACAGAGAATAAGAATGATGAAA
GAATTAGATGTATGTTCACCTGAATTTAGTTTCTTGAGAGCAGAAAGTGAAGTTAAAAAA
CAGAAAGGCCGGATGCTAGGTGATGTGCTAATGGATCAGAACGTATTGCCTGGAGTAGG
GAACATCATCAAAAATGAAGCTCTCTTTGACAGTGGTCTCCACCCAGCTGTTAAAGTTTG
TCAATTAACAGATGAACAGATCCATCACCTCATGAAAATGATACGTGATTTCAGCATTCT
CTTTTACAGGTGCCGTAAAGCAGGACTTGCTCTCTCTAAACACTATAAGGTTTACAAGCG
TCCCAATTGTGGTCAGTGCCACTGCAGAATAACTGTGTGCCGCTTTGGGGACAATAACAG
AATGACATATTTCTGTCCTCACTGTCAAAAACTCGAGCACCACCACCACCACCACTGAGA
TCCGGCTGCTAACAAAGCCCGA 
 
 
